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The public health significance of this work reflects the HIV/AIDS epidemic and the 
growing concerns of long-term consequences of antiretroviral therapy.  The advent of highly 
active antiretroviral therapy (HAART) has greatly improved survival among those with HIV-
infection. As a corollary, clinicians and researchers face a range of long-term complications 
previously of little importance to HIV-infected patients. HIV-associated lipodystrophy 
syndrome (HIV-LS) was first described in 1998 and involves a constellation of metabolic 
and morphologic abnormalities. Whereas AIDS wasting syndrome has been associated with 
immunosuppression and high viral burden, HIV-LS has been documented with 
immunocompetence and suppressed viral concentration.  Participants of the local site of the 
Multicenter AIDS Cohort Study (MACS) consented to photography of their lipodystrophic 
body habitus changes during routine clinic appointments. The compilation of these 
photographs was used to develop a manual for clinicians at all four of the MACS sites in 
order to accurately document the syndrome, and permitted initial classification of HIV-LS 
into two phenotypes. A third phenotype was identified following a preliminary observation 
of lipoaccumulation extending bilaterally and symmetrically from the breasts laterally into 
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the axilla. Additional cases were subsequently identified within the MACS; all subjects had 
pre-existing lipoaccumulation of at least one other anatomical site. It was speculated as to 
whether this represented a previously unrecognized evolution of HIV-LS.  Our next project 
involved studying the health related quality of life (HRQL) of men with HIV-LS. We found 
HIV-LS does not negatively affect HRQL or exacerbate depressive symptoms above and 
beyond the diagnosis of HIV-infection.  The metabolic abnormalities of HIV-LS include 
insulin resistance and dyslipidemia, both of which are considered pro-atherogenic risks. The 
final segment of this project involved detecting coronary artery calcification via electron 
beam computed tomography among HIV-infected men treated with HAART. In this male 
population with well controlled HIV-infection, chronic use of HAART did not impact the 
progression of subclinical coronary atherosclerosis.  In contrast, traditional atherosclerosis 
risk factors of smoking and advancing age were predictive of coronary atherosclerosis. HIV-
infection requires life-long combination treatment. Clinicians, researchers and patients 
recognize dyslipidemia, peripheral lipoatrophy and central lipohypertrophy as significant 
consequences of this combination therapy, and hope that concerns regarding increasing 
cardiac risk are not warranted.     
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1.0  BACKGROUND AND LITERATURE REVIEW 
Prior to the advent of highly active antiretroviral therapy (HAART), increased fasting 
triglycerides (1) and decreased serum cholesterol levels (2)  were among the first metabolic 
abnormalities associated with immunodeficiency virus (HIV) infection. (1-5) A range of 
metabolic abnormalities are found among patients with acquired immunodeficiency syndrome 
(AIDS),  including lower high-density lipoproteins (HDL) levels and a greater proportion of  low 
density lipoprotein (LDL)-B phenotype, which is strongly associated with insulin resistance. (6)  
In aggregate, hyperlipidemia, insulin resistance, fasting hyperglycemia, central obesity, and 
peripheral lipoatrophy comprises HIV lipodystrophy syndrome (HIV-LS). This syndrome was 
first described in 1998 in response to self-reports by HIV-infected individuals. (3)  The reported 
prevalence of HIV-LS varies widely among cross-sectional studies, reflecting the absence of a 
standardized case definition. (3,7) Techniques used to establish the diagnosis range from self-
report only to those which include some form of imaging, such as magnetic resonance imaging 
(MRI), computed tomography (CT) or dual energy X-ray absorptiometry (DEXA), though the 
use of these imaging approaches have not been supported or justified by existing data.  Most 
often, the diagnosis relies on a combination of self-report and clinician assessment, and is 
quantified by the degree of change in the distribution of body fat. Whereas AIDS wasting 
syndrome has been characterized by muscle mass loss, associated  with immunosuppression and 
high viral burden, HIV-LS has been documented with immunocompetence,  suppressed viral 
load (3) and a disproportionate loss of adipose tissue. (3,7)  
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Initially, protease inhibitor (PI) use was implicated as the cause of HIV-LS; however, 
more extensive research and follow-up efforts have documented such findings in patients with 
HIV unexposed to PI. (7)  These metabolic abnormalities, however, can be exacerbated by 
additional metabolic derangements associated with commonly used highly active antiretroviral 
therapies (HAART) regimens. HAART regimens, particularly their PI components, have 
revolutionized the treatment of HIV infection through potent viral suppression and have led to a 
significant reduction in new AIDS cases and deaths. These therapies, however, have been 
associated with elevations in serum triglycerides, insulin resistance, fasting hyperglycemia, and 
lipodystrophy with central adiposity. (3,7)  HAART-associated hyperglycemia and lipid 
abnormalities may emerge rapidly after drug therapy begins and may be quite extreme, with 
hypertriglyceridemia exceeding 1000 mg/dL at times. (4) Hewitt and colleagues reported 
increases in serum triglycerides from a median of 298 mg/dL to 1803 mg/dL after a mean 
treatment period of 223 days among patients on a PI-containing regimen. (8)  Carr, et al reported 
lipid abnormalities among 74% of patients taking PI for a median of 21 months. (3)  
Additionally, these effects are not limited to adults; dyslipidemia has been reported among 
children taking HAART even among those without a history of familial hypercholesterolemia. 
(9) While HIV-LS is intriguing to clinicians and researchers, it is disturbing to those who 
experience it.  Individuals are often concerned that abnormal body habitus changes will make 
their HIV-infection obvious to others, and they may alter activities of daily living in order to 
conceal these changes.  Such activities may negatively impact their quality of life and adherence 
to their antiretroviral medications.    
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The advent of HAART has greatly improved survival among those with HIV, meaning 
clinicians and patients now face a range of long-term complications previously of little 
importance to HIV patients. During the era of untreated HIV-infection, morbidities and 
mortalities resulted primarily from infection and malignancy.  Now, the long-term consequences 
of HIV-infection and the side effects of potent therapies, including metabolic and body habitus 
changes pose different concerns. (3,7,10,11) Specifically, as those with HIV-infection age, they 
are subject to the same complications of increased serum triglycerides and insulin resistance as 
their non-HIV infected peers, including coronary artery disease, myocardial infarction, 
peripheral vascular disease, cerebrovascular accidents, pancreatitis and type II diabetes mellitus. 
(10,11) Several cases of premature atherosclerosis and cardiac events have been described 
among patients treated for HIV-infections among patients with and without traditional risk 
factors. (12)  Thus, the relationship between metabolic toxicities, HAART therapy and increased 
cardiovascular risk has become an area of intense research, especially as increasing numbers of 
patients face decades of antiretroviral therapy. 
1.1 TREATMENT OF HIV INFECTION 
Since the development of zidovudine (ZDV) in 1987 and the subsequent approval of other 
nucleoside reverse transcriptase inhibitors (NRTIs), the treatment for HIV infection has evolved 
dramatically.  NRTIs effectively suppress viral replication by incorporating into the viral DNA 
as it enters the human cell nucleus. ZVD monotherapy was used for several years until viral 
resistance rendered it ineffective. Subsequently, combination regimens including NRTI 
components dominated treatment until the mid-1990s when PIs were introduced.  
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PIs inhibit viral replication by preventing reassembly of viral proteins and release from 
infected human CD4 cells.  With the introduction of PIs, the standard of HIV care incorporated 
both NRTIs and PIs. The addition of non-nucleoside reverse transcriptase inhibitors (NNRTIs) to 
the anti-HIV arsenal in 1998 further broadened clinicians’ options. NNRTIs bind directly to 
reverse transcriptase thereby preventing the conversion of viral RNA to viral DNA.   
Enfuvirtide (Fuzeon®), a fusion inhibitor is one of the newest HIV treatments, approved 
for experimental use in the United States March 13, 2003. Enfuvirtide has a unique mechanism 
of action which blocks viral particles from adhering to, and thus prevents entry into, human 
CD4+ cells. The latest research and development has focused on inhibiting CCR5 entry and 
integrase.  CCR5 is a receptor on T-lymphocytes that circulating HIV uses to attach to the cell.  
CCR5 entry inhibitors alter the shape of the CCR5 which prevents HIV from successfully 
adhering to the cell.  Integrase inhibitors interfere with the enzyme necessary to permit HIV from 
integrating its genetic material into human DNA for replication.    
The current standard of care is to prescribe potent regimens consisting of at least two 
NRTIs, and at least one PI or at least one NNRTI; or triple nucleoside therapy in the case of prior 
treatment failure. Since these classes of medications are effective in different stages of viral 
replication, using them in combination most efficiently reduces viral burden. HAART is not 
curative, however, and HIV-infected patients can expect to take some combination of 
antiretroviral medications for the rest of their lives. When taken as prescribed, these potent 
regimens reduce viral load to undetectable levels in the blood in most patients. While HAART 
has dramatically decreased the rates of opportunistic infections, delayed the diagnosis of AIDS, 
and improved life expectancy, there are serious side effects which may alter patients’ adherence 
rates.  These side effects include gastrointestinal upset, hyperglycemia, nephrolithiasis, 
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pancreatitis, accumulation and redistribution of body fat and severe lipid abnormalities (1,3-
5,8,11) and their degree and impact can vary significantly among individuals. For some, 
treatment effects can negatively impact quality of life.  Reflecting the growing awareness of 
medication-related toxicities, adverse reactions and complications, many researchers and 
clinicians are advocating postponing treatment.  In the past, guidelines recommended 
pharmacologic therapy for patients with CD4 counts below 500 cells/mm3 and a viral load above 
20,000 copies/ml. (13) The most recent Adult and Adolescent HIV treatment guidelines were 
released January 29, 2008 and recommend delaying therapy in asymptomatic patients until the 
CD4 count is below 350 cells/mm3.  (14)    
1.2 HIV-ASSOCIATED LIPODYSTROPHY SYNDROME 
HIV-LS involves a constellation of metabolic abnormalities and body habitus changes including 
hyperlipidemia, insulin resistance, hyperglycemia, central adiposity and peripheral lipoatrophy. 
(3,7,15) Neither strict diagnostic criteria nor case definition currently exist. In 2003, Carr and 
colleagues proposed a detailed HIV-LS case definition however, as it required medical imaging, 
many clinicians and researchers considered it cost prohibitive. (7) Currently, documentation of 
the syndrome relies on subjective measures such as patient self-report and/or clinician report.   
1.2.1 Glucose homeostasis 
Normal glucose homeostasis is an intricate process that requires both adequate pancreatic beta 
cell production of the hormone, insulin, and the appropriate binding of this hormone to cell 
surface insulin receptors. The pairing of the hormone with its receptor facilitates the entry of 
glucose into cells.  Abnormalities of any part of the process can lead to glucose intolerance or 
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frank diabetes. Diabetes mellitus type I results from absolute pancreatic beta cell failure and a 
complete absence of insulin.  In contrast, those with diabetes mellitus type II have a relative 
insulin deficiency resulting in hyperglycemia or insulin receptor abnormalities which lead to 
resistance to the actions of insulin even in the presence of normal or high levels of the hormone.  
The American Diabetes Association defines diabetes mellitus (DM) as fasting blood 
glucose greater than 126 mg/dL or a post-prandial glucose exceeding 200 mg/dL.  In the absence 
of true DM, two other related pathologies can exist: impaired glucose tolerance, defined as 
postprandial hyperglycemia associated with normal fasting glucose levels, and insulin resistance, 
characterized by impaired insulin utilization by peripheral tissues. In the presence of insulin 
resistance, high concentrations of insulin are required to drive glucose into muscle and fat cells.  
Insulin resistance was first described in the early 1940s.  At the time, endogenous insulin 
levels could not be measured; however, Himsworth noted that in some diabetic patients the 
administration of exogenous insulin did not cure their diabetes and he postulated other 
mechanisms were responsible for their hyperglycemia. (16) Decades later, Yallow and 
colleagues reported elevated insulin levels among patients with type II DM. (17)  Insulin 
resistance has been identified as a risk factor for coronary artery disease, (18) a relationship 
likely mediated through associated endothelial dysfunction and the prothrombotic, 
proinflammatory effects of vascular injury. (19,20)  
Disorders of glucose homesostasis, including impaired glucose tolerance, insulin 
resistance and diabetes mellitus, are more prevalent among patients taking HAART than among 
the general public. Conservative estimates of insulin resistance in HIV-infected individuals range 
from 1%-6%, (21) and impaired glucose tolerance likely affects an even greater percentage. The 
findings appear attributable, in some measure to HIV itself and some to its treatment. Noor and 
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colleagues described new-onset insulin resistance among a cohort of HIV-negative subjects who 
were given protease inhibitors for as little as 4 weeks. (22,23)  Data by Dube et al also support a 
treatment-related effect; in their work, withdrawing protease inhibitors reversed some 
hyperglycemia associated with medication use. (24)   
In 2004, a large prospective study was conducted within the Multicenter AIDS Cohort 
Study (MACS) to ascertain the prevalence and incidence of diabetes mellitus among HIV-
infected men. (25) DM was defined as a fasting glucose measurement of at least 126mg/dL, a 
self-reported history of DM or use of diabetes medication.   After adjusting for age and body 
mass index, the authors found a DM prevalence of 14% prevalence among HIV-infected men 
treated with HAART compared to a 5% among seronegative men (prevalence ratio 4.6; 95% CI, 
1.85-9.16).  (25) After a mean follow-up time of 2.4 years, 5% (38/680) of those men initially 
without DM met the diagnostic criteria.  Twenty-four of these new cases (63%) were among 
HIV-infected men treated with HAART while the remaining four cases were among HIV-
infected patients treated with non-HAART regimens.   These results supported previous findings 
of an increased prevalence of DM among HIV-infected individuals undergoing treatment and 
underscored the particular association of DM with HAART therapy as these patients had DM 
rates four times higher than seronegative male counterparts. (25) 
1.2.2 Dyslipidemia and HAART 
Elevated serum cholesterol, LDL and triglycerides, and low levels of HDL are independent risk 
factors for coronary artery disease. (25 -28)  The Third Report of the National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) identified high and optimal serum lipids 
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relative to coronary artery disease risk for patients with and without additional risk factors. (28) 
(Table 1) 
 
 
Table 1. Serum lipid concentrations relative to coronary artery disease risk 
 
 
Serum Values Stratification of high serum 
concentration 
Optimum concentration 
Total Cholesterol >  240 mg/dL < 200 mg/dL 
LDL Cholesterol 
*goals are based on risk factors, 
especially existing coronary artery 
disease 
> 160 mg/dL 
* without coronary artery disease and 
< 2 risk factors 
< 100 mg / dL 
*with history of coronary artery disease 
Triglycerides > 400 mg/dL < 200 mg/dL 
 
Antiretroviral therapy negatively impacts both lipid transport and metabolism. (21) The 
exact mechanism of antiretroviral induced hyperlipidemia is beyond the scope of this work, but 
in summary, involves increased production of very low density lipoproteins (VLDL), excessive 
free fatty acid mobilization and impaired lipoprotein clearance. (29)  These abnormalities most 
likely result from concomitant insulin resistance that prevents efficient fat cell storage of 
triglycerides.  These triglycerides circulate, manifesting as elevated free fatty acid concentrations 
that facilitate hepatic secretion of VLDL.  
Antiretroviral associated dyslipidemia has been reported to occur within weeks of 
initiation. (1)  Carr and colleagues found a 74% prevalence of lipid abnormalities in patients 
taking protease inhibitors for a median of 21 months. (3) Protease inhibitors have even caused 
elevations in lipids in HIV-infected children without familial hypercholesterolemia. (9) Both 
HIV and the antiretroviral therapies have been suspected in causing the hyperlipidemia, although 
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no exact mechanism has been proven. (2,5)  There are conflicting results with regard to the 
incidence and severity of antiretroviral therapy induced dyslipidemia.  
Protease inhibitors were the first components of HAART to be implicated in treatment-
induced hyperlipidemia. Initial prevalence reports varied, though, from 8% to 66%. (30)  Hewitt 
documented a 6-fold increase in serum triglycerides (mean 298 – 1803 mg/dL) among patients 
who had received a protease inhibitor regimen for a median of 223 days. (8) In that study, 
triglycerides were lowered to a median level of 300 mg/dL after three months of treatment with 
gemfibrozil. (8) 
One retrospective study has been performed comparing pre-seroconversion lipid profiles 
to those after approximately three years of treatment with HAART (N=50 men). (1) Authors 
described a mean decline of -30 mg/dL of cholesterol, and a mean LDL-C decline of -22 mg/dL 
after HIV-infection. Following treatment with HAART, the triglycerides and total cholesterol 
levels increased. It was suggested that the post-treatment increases in triglycerides and 
cholesterol represented a re-approximation to baseline levels. These findings support the concept 
of increasing age causing the increase in serum lipids rather than treatment with HAART. (1) 
The magnitude of antiretroviral mediated dyslipidemia appears to vary by drug. For example, the 
protease inhibitor ritonavir, and the NRTI stavudine (d4T, zerit) have been associated with 
extreme dyslipidemia. (2,5) Although all protease inhibitors have been associated with some 
degree of dyslipidemia, ritonavir is the one most often implicated in severe abnormalities. (5)  
With longer periods of observation, nucleoside reverse transcriptase inhibitors are also now 
known to be involved. 
 Some researchers have investigated the putative role of protease inhibitors in HIV-
related hyperlipidemia by substituting different medications and observing changes in serum 
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lipids.  Results have been inconsistent. (Table 2) Periard reported improvement in serum 
cholesterol and triglycerides in seven patients 29-63 days after substituting nelfinavir or 
indinvavir for ritonavir. (31)  In a larger study among 40 patients, Tebas described a 31% 
decrease in triglycerides (p=0.005) and an 11% decrease in cholesterol (NS) during a 24 week 
follow up period when subjects’ protease inhibitors were replaced with nevirapine. (32)  Among 
twenty patients with undetectable viral load and HIV-LS syndrome, the investigators from the 
Scandinavian Simvastatin Survival Study (4S) reported a 31% triglycerides reduction (p=0.03) 
within 6 months following substitution of efavirenz for the patients’ protease inhibitors. (33) 
Total cholesterol did not change. In the Tabas trial, one patient whose viral load was initially 
undetectable developed detectable virus after protease inhibitor discontinuation. (32) Upon 
protease inhibitor re-initiation, the viral load again became undetectable. (32) In the 4S trial, all 
study participants had undetectable viral loads at baseline and one developed detectable virus 
within the 6 month follow-up period. (33) 
Some researchers have found no lipid improvement when PI were excluded from HIV 
regimens. Gharakhanian reported that among thirty-one subjects who substituted efavirenz for 
their PI, no change in serum lipids emerged after 10 months of observation. (34)  In a study by 
Vicinana and colleagues, thirty-nine patients received efavirenz in place of their protease 
inhibitor. (35) During follow-up time, total cholesterol, LDL and triglycerides actually increased 
slightly.  (35) 
Barriero completed the largest study; 138 subjects were randomized to either continue PI 
or replace a PI with nevirapine. (36) Both groups had similar lipid profiles at baseline. In the PI 
group, mean triglycerides were 284 (±346) mg /dL and mean cholesterol was 249 (±77) mg/dL.  
The nevarapine-treated group had mean triglycerides of 292 (±352) mg/dL and mean cholesterol 
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of 242 (± 102) mg/dL. After 6 months, no changes in cholesterol, triglycerides or viral 
suppression developed. (36)   
 
Table 2. Changes in antiretroviral regimens and effect on serum lipids 
 
Researcher / Study N 
 
Medication change Outcome 
Periard 1999 7 Rit → Nelfinavir or 
Indinavir 
 
↓ cholesterol and 
triglycerides after 29-63 
days 
Tebas 2000 40 PI → Nevirapine ↓   cholesterol by 11% 
(NS) and ↓ triglycerides by 
31% (p=0.005) after 24 
weeks 
Scandinavian (4S) 1994 
 
20 PI→ efavirenz ↓ triglycerides 31% 
(p=0.03) and no change in 
cholesterol 
Viciana 2000 39 PI→ efavirenz Slight ↑ in cholesterol, 
LDL, triglycerides and 
HDL 
Gharakhanian 2000 
 
31 PI→ efavirenz No change in lipids after 
10 months 
Barreiro 2000 138 Randomized to continue 
PI or → Nevirapine 
 
No change in lipids after 6 
months 
 
 
1.2.3 Pharmacologic treatment for dyslipidemia 
In response to the prevalence of antiretroviral associated dyslipidemia, most clinicians now 
routinely monitor fasting triglycerides and cholesterol in 3-4 month intervals in patients who are 
infected with HIV and treated with antiretroviral therapy. Those HIV-positive patients with 
triglycerides in the range of 500-1000 mg/dL, LDL exceeding 160 mg/ dL, and those with LDL 
exceeding 130 mg/dL in the presence of coronary artery disease, often require more frequent 
assessments.  
Among patients taking HAART, hypertriglyceridemia may be complicated by additional 
metabolic abnormalities, further complicating the management of HIV-infected individuals. 
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Goals of lipid lowering treatment are based on the presence of additional cardiac risk factors.  
Lipid-lowering agents are effective for secondary prevention as well, and decrease the risk for 
subsequent cardiac events among those with existing CAD by improving endothelial function, 
decreasing platelet activity and decreasing inflammation.  
Although there are some very specific guidelines for treating hyperlipidemia in the 
general population, (4) the management in HIV-infected individuals is much more complex.  
Guidelines have been proposed for treatment of antiretroviral- induced hyperlipidemia. (4)  An 
additional challenge in the treatment of those with antiretroviral-associated hyperlipidemia is that 
most patients exhibit combined lipid abnormalities encompassing both cholesterol and 
triglyceride abnormalities. (1,3,4)   Furthermore, common lifestyle recommendations for 
cholesterol management such as aerobic exercise and weight reduction may not suit some HIV-
infected patients struggling to maintain or regain weight lost due to HIV wasting syndrome.  
Specific low-fat diets may also conflict with antiretroviral regimens.  For example, saquinavir 
(invirase) should be taken within two hours of a high fat meal.  These examples highlight the 
particular limitations of non-pharmacologic techniques among those infected with HIV. Thus, 
lipid lowering agents often become the first-line treatment options.  These agents must be 
prescribed with caution; however, as patients frequently take several medications which 
increases the risk for drug interactions. Additionally, many individuals with HIV-infection have 
concomitant hepatitis B or hepatitis C virus infection which may be associated with hepatic 
insufficiency and abnormal clearance of hepatically metabolized medications, such as statins.   
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Table 3: Effects of lipid-lowering medication and potential adverse effects 
 
Medication 
Class 
Serologic effects Potential Side Effects 
HMGCoA reductase inhibitors (Statins) ↓ LDL 
↓TG 
↑HDL 
Hepatic dysfunction 
Myopathy 
Bile acid sequestrants ↓ LDL 
↑HDL 
Gastrointestinal upset 
Drug/drug interactions 
Nicotinic acid ↓ LDL 
↓TG 
↑ HDL 
 
Gastrointestinal upset 
Hyperglycemia 
Hyperuricemia 
Hepatic dysfunction 
Fibric Acid ↓ LDL 
↓ TG 
↑ HDL 
Myopathy 
Dyspepsia 
Gallstones 
 
 
The primary goal of lipid lowering therapy is to reduce levels of atherogenic low-density 
lipoproteins.  There are several classes of lipid-lowering medications currently available and 
include statins, bile acid resins, fibric acid derivatives, nicotinic acid and fibric acid. (Table 3)   
The most common class of lipid lowering medications is HMG-CoA reductase inhibitors, 
or statins.  They lower plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA 
reductase and preventing cholesterol synthesis in the liver.  They also increase the number of 
hepatic LDL receptors on the cell-surface which facilitates uptake and catabolism of LDL and 
reduce LDL production.  HMG-CoA reductase inhibitors also decrease the lipid content of 
atherosclerotic plaques, thereby making them more stable and less prone to rupture. Among the 
statins, atorvastatin (Lipitor) is most commonly prescribed to HIV-infected individuals because 
of its potent antihypertriglyceridemic effects.  Pravastatin (Pravachol) is also commonly used in 
the HIV-infected population.  Two other statins, simvastatin (Zocor) and lovastatin (Mevacor) 
are not recommended for use with protease inhibitors as both undergo cytochrome 3A4 
metabolism and this shared metabolic pathway raises the likelihood of adverse effects.      
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Bile acid resins or bile acid sequestrants bind cholesterol-containing bile in the intestines; 
it is subsequently eliminated in the stool. Resins lower both serum cholesterol and LDL and are 
commonly used in combination with other lipid-lowering drugs. However, such combinations 
may raise triglycerides and therefore may not be optimal for use in those with mixed-
abnormalities as is commonly found in HIV-infection. (4,5) Resins also require dosing three 
times daily at least two to three hours before or after other medications, a potentially unrealistic 
schedule for those already taking a complex HIV treatment regimen. When taken too soon after 
or before other medications, such as antiretrovirals, bile-acid resins may adversely affect their 
absorption.  
Among the other agents to treat high cholesterol, clinicians generally avoid the use of 
niacin because of the possibility in exacerbating insulin resistance. (5) Another class of agents, 
the fibric acid derivatives, effectively lowers serum triglycerides between 30% and 55%; 
however, they are not used as first-line therapy due to their limited effects on total cholesterol 
and LDL levels. (5) HIV-infected patients with extreme hypertriglyceridemia frequently benefit 
from a combination of gemfibrozil and a statin, although such combinations increase the risk of 
rhabdomyolysis. (5) When lipid lowering therapy is initiated, lipid profiles generally improve 
within 6 months.   
1.2.4 Body habitus changes 
HIV lipodystrophy syndrome was first described in 1998 following self-reports among HIV-
infected patients.  The syndrome involves four important components: hyperlipidemia, fasting 
hyperglycemia, insulin resistance and body habitus changes.  The lipodystrophic body habitus 
changes fall into two patterns. Phenotype I involves lipoatrophy only while phenotype II 
involves a combination of lipoatrophy and lipohypertrophy, often referred to as mixed 
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lipodystrophy. Lipoatrophy presents as loss of subcutaneous fat in the nasolabial folds and 
temporal regions of the face, extremities and buttocks. Lipohypertrophy presents to varying 
degrees in both genders as increased fats stores in the breasts, abdominal visceral compartment 
and the dorsocervical fat pad. (37)  The latter is not the result of hypercortisolism. (37) Other 
areas may undergo lipohypertrophy as reports of occipital fat and circumferential neck 
accumulation, so called “Magedelen’s collar” or “horse collar” have emerged.   
Changes in visceral fat are generally assessed subjectively by clinician or patient report 
complemented by quantification using anthropometric measures. Attempts to measure visceral 
fat more precisely have included MRI, DEXA, and CT imaging. (7) These approaches provide 
more via continuous, rather than the dichotomous data which notes only the absence or presences 
of lipodystrophy. The costs for imaging modalities, however, are prohibitive for routine clinical 
use.   
The reported prevalence HIV-LS has varied widely, and initially, protease inhibitors were 
hypothesized to be the primary cause. Particularly when severe, HIV-LS can be distressing 
enough patients may request a change in antiretroviral regimens even if such regimens have been 
successful in viral suppression. In response, new antiretroviral regimens have been developed 
which do not include this class of medications.  Additional potential advantages of these protease 
inhibitor-sparing combinations may include fewer drug interactions, fewer pills which may 
enhance compliance, and fewer side effects, including lipodystrophy. It is not known, however, 
whether such protease-sparing regimens will suppress viral replication as well.  Furthermore, as 
data have accrued, similar findings have been documented in HIV-infected patients not receiving 
protease inhibitors and among non-HIV infected patients. 
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2.0  SPECIFIC AIMS 
The primary purpose of this work was to document long-term effects of HAART on body 
habitus and to determine the risk of subclinical coronary atherosclerosis among a cohort of HIV-
infected men treated with HAART.   
      
Specific Aim #1 – Photograph and characterize patterns of body habitus changes 
consistent with HIV-associated lipodystrophy syndrome (HIV-LS) in HIV-infected men treated 
with HAART, and develop a manual for clinicians to use in the Multicenter AIDS Cohort Study 
(MACS) to accurately and consistently document HIV-LS. 
Specific Aim #2 – Describe a third phenotype of HIV-LS among subjects within the 
MACS.   
Specific Aim #3 - Describe quality of life patterns among HIV-infected men with body 
habitus changes and HIV-LS.   
Specific Aim #4 – Document prevalence of coronary artery calcification via electron 
beam computed tomography among a cohort of 80 HIV-infected men taking HAART, and 
document risk factors for progression of coronary artery calcification via electron beam 
computed tomography. 
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 3.0  PREFACE TO FIRST PUBLICATION 
Body habitus changes can be difficult to appreciate due to the natural variation of body shape, 
contour and size. Some people many appear to have “mild lipodystrophy” as a consequence of 
weight gain or aging.  While experienced clinicians are able to distinguish true, even subtle HIV-
associated lipodystrophic changes from age or obesity-related phenomena, such distinctions may 
be challenging, particularly in settings staffed by significant numbers of less experienced rotating 
residents and fellows, such as found at several MACS sites.  Within the MACS, HIV-LS-
associated body habitus changes have been assessed using self-report, clinician report, and 
anthropometric measurements obtained at the iliac crest, across the buttocks, at the midpoint of 
the arm and the midpoint of the thigh (estimated to the closest centimeter for the waist and hips 
and the closest 0.1 cm for the extremities). Skin-fold measurements were initially used but were 
discontinued after such data were deemed unreliable.    
MACS investigators determined that a comprehensive manual providing technique to 
facilitate a thorough examination and providing illustrations of the potential range of HIV-LS 
severity would improve the quality and reliability of HIV-LS assessments.  Thus, the manual, 
“Documenting HIV-associated Lipodystrophy Syndrome (HIV-LS) within the Multicenter AIDS 
Cohort Study,” was created to establish consistent assessment of HIV-LS among all four of the 
MACS sites.  
Clinicians within the MACS assessed each subject during every clinic visit for the 
presence and severity of HIV-LS using physical examination and study participant report. 
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Clinicians initiated participant self-report by asking about changes in the distribution or amount 
of body fat (either loss or gain) in the previous 6 months.  If such changes were acknowledged, 
participants were then asked to identify affected areas (face, arms, legs, buttocks or dorsocervical 
region), and to describe the severity of changes in each.  Subjects were also asked to describe 
increases, if any, in neck or waist circumference, using increments of less than 1 inch, between 
1and 2 inches or exceeding 2 inches.   
Using prospectively collected data, HIV-LS cases within MACS were characterized as 
“stable,” defined as those whose phenotype has remained consistent over time, “developmental,” 
defined as those unaffected or only mildly affected at baseline who are subsequently found to 
have developed lipodystrophic changes, or “transitional,” defined as those with evidence of one 
lipodystrophic phenotype at baseline and a different phenotype at subsequent follow-up.   
 These descriptions were accompanied with photographs which were found to be vital to 
both identifying and monitoring HIV-LS onset and progression. Of note, many study participants 
were grateful that photographic evidence validated the changes they described.  
The severity of HIV-LS was quantified as “mild,” “moderate” or “severe” defined as 
follows. “Mild” defined changes evident to the clinician with close inspection; “moderate” 
defined changes evident without specific inspection and “severe” reflected changes evident to 
non-medical person by casual observation. In addition, objective data including standardized 
anthropometric measurements of height, weight, and arm, thigh, waist and hip circumferences 
and laboratory testing, including lipid profiles, glucose, insulin and glycosolated hemoglobin, 
were obtained.  
Subjects in the MACS who were identified as having lipodystrophy were aware of our 
attempt to identify risk factors and granted permission for photography of HIV-LS affected body 
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areas.  Photographs were taken exclusively by a Pitt Men's Study clinician for use exclusively in 
education and research.  
 
3.1 SPECIFIC AIM #1 
Specific aim #1, photograph and characterize patterns of body habitus changes consistent with 
HIV-LS, is addressed in an internal publication within the MACS, and represents the most 
comprehensive photographic compilation of HIV-associated lipodystrophy in the country.  This 
45 page manual , “Documenting HIV-associated Lipodystrophy Syndrome (HIV-LS) within the 
Multicenter AIDS Cohort Study” provides information on performing the clinical assessment for 
HIV-LS and includes photographic examples of mild, moderate and severe physical findings.  
This manual was circulated to all four of the MACS sites during the summer of 2007. (Appendix 
1) The manual was reviewed favorably by clinicians and was reformatted and condensed into a 
pocket version in the summer of 2008. (Appendix 2)  
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4.0  PREFACE TO SECOND PUBLICATION 
 As previously described, the MACS assessment for HIV-LS involved inspection, 
anthropometric measurements, subcutaneous fat caliper measurements and photography.  
Initially, MACS researchers proposed 2 phenotypes of HIV-LS: phenotype I with isolated 
lipoatrophy and phenotype II which involved concurrent lipoatrophy and lipohypertrophy. (15)  
During a clinical encounter with a seropositive MACS patient, however, a distinct and unique 
pattern of lipoaccumulation was noted.  This pattern was characterized by supradiaphramatic fat 
which extended laterally from the breasts in the absence obvious breast masses or fluid 
accumulation.  This band-like accumulation of fat was non-tender and without overlying skin 
changes.  No aspects of the patient’s medical history accounted for these changes.   In 
consultation with clinicians from the other MACS sites, these photographs were distributed to 
ascertain prevalence of this abnormal fat distribution.  Once the photographs were viewed, 
additional cases were identified in Chicago, Baltimore and Los Angeles.  It appeared that a new 
pattern of lipodystrophy notable for simultaneous fat accumulation and lipoatrophy had been 
recognized.   
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4.1 SPECIFIC AIM #3 
Specific aim #2, to describe a third phenotype of HIV-LS, is addressed in a manuscript originally 
published in The Journal of the American Medical Association. Permission for reprint in this 
doctoral dissertation was granted March 13, 2008.   
 
4.2 A NOVEL PATTERN OF LIPOACCUMULATION IN HIV-INFECTED MEN   
Frank J Pallela1, Joan Chmiel1, Sharon Riddler2, Bridget Calhoun3, Adrian Dobbs4, Barbara 
Visscher5, Lawrence Kingsley3   
1Feinberg School of Medicine, Northwestern University Chicago, Ill; 2School of Medicine, 
University of Pittsburgh, Pittsburgh, PA; 3Graduate School of Public Health, University of 
Pittsburgh, Pittsburgh, PA; 4Johns Hopkins University Medical School, Baltimore, MD; 
5University of California at Los Angeles College of Medicine, Los Angeles, CA.  
JAMA 2006 296(7):766-68. Copyright © 2006 American Medical Association. All rights 
reserved.  
4.2.1 Introduction 
Body habitus changes among persons infected with human immunodeficiency virus (HIV) who 
receive highly active antiretroviral therapy (HAART) are major concerns, in part because of their 
frequent association with insulin resistance and hyperlipidemia. The desire to avoid such changes 
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has influenced selection of antiretrovirals and timing of HAART initiation. Lipoatrophy is of 
particular cosmetic concern to affected individuals. It is most commonly manifested as limb and 
gluteal fat loss with consequent apparent thinning of the extremities and facial fat loss with a 
“sunken cheek” appearance. (7,38)  Lipoaccumulation most often appears as visceral abdominal 
adiposity with increased abdominal girth. Other manifestations include dorsocervical fat pads 
(“buffalo humps”) and neck lipoaccumulation (“bull neck”). 
We report what we believe to be a novel manifestation of lipoaccumulation in 8 men with 
HIV infection.  
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Figure 1. Example of a novel type of lipoaccumulation in men infected with Human 
Immunodeficiency Virus 
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 4.2.2 Methods 
All individuals are HIV-infected participants in the Multicenter AIDS Cohort Study (MACS), a 
longitudinal study of men who have sex with men.  The original cohort included 5622 men. 
Since 1984, MACS participants have undergone clinical evaluation twice yearly. Since 1999, 
anthropometrics (height; weight; and circumference of chest, waist, hip, thigh, and mid proximal 
arm) and examiner- and self-reported body habitus changes have been recorded, as have 
diagnoses of hyperlipidemia, hyperglycemia, diabetes mellitus, and hypertension.  Blood 
measurements include serum lipid levels, glucose levels, and CD4 cell count determinations.  
Patients self-designate race.  Institutional review board approval was obtained for MACS and all 
participants gave written informed consent. 
4.2.3 Results 
An initial observation of a novel type of lipoaccumulation was made by a MACS clinician in 
Pittsburgh, PA.  Seven other cases were subsequently identified study-wide. Mean age was 44.6 
year (range, 39-52 years).  Six patients were white and 2 were Asian/Pacific Islander.  
All patients had bandlike accumulations of lipomatous-appearing tissue extending 
bilaterally and symmetrically from the breasts laterally into the axillae. (FIGURE 1)  In some 
patients, this fatty tissue extended further posteriorly, with a near circumferential distribution. 
None of these persons had notable soft tissue nodularity, tenderness, evidence of mastitis or other 
acute inflammation or infection, or the presence of new or enlarged axillary lymphadenopathy.  
None had hypogonadism.  All had preexisting lipoaccumulation (evidenced in at least 1 other 
bodily area [eg abdomen, dorsocervical area]) before the unique pattern of lipoaccumulation  was 
noted but not before HAART was initiated; 6 had limb and facial lipoatrophy. (TABLE 4) Body 
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mass index measurements were not indicative of obesity.  Four of the 8 participants reported a 
history of hyperlipidemia; none reported a history of hyperglycemia or diabetes mellitus.  
One participant had a history of an AIDS-defining illness; 3 had a nadir CD4+ cell count 
of less than 200/µL. (TABLE 5)  Mean number of years of antiretroviral therapy received at the 
time of identifying the lipoaccumulation was 7.8 (range, 4.5-13 years). (TABLE 6) Six patients 
were receiving HAART at the time of identification, 4 with regimens including protease 
inhibitors.  All participants had elevation in at least 1 measurement of serum low-density 
lipoprotein cholesterol, triglycerides, or total cholesterol during at least one visit.  
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Table 4. Patient clinical characteristics  
 
 
Patient Years ^ Baselin
e BMI* 
Most 
recent 
BMI* 
Lipoatrophy Abd 
girth 
Dorsocervic
al fat pad 
Breast 
enlargement 
Chest 
circumference 
(cm) 
Arm 
Circumference 
(cm) 
1 11.3 23.6 23.4 ++ + + + NA NA 
2 0.0 27.1 27.1 ++ _ + + 103.0 28.0 
3 16.7 21.7 23.2 ++ + + + 101.0 28.5 
4 13.7 27.0 31.2 ++ _ + _ 123.0 38.5 
5 17.1 20.4 25.2 ++ + + _ 115.0 35.5 
6 16.6 21.9 27.1 _ + _ _ 104.0 35.0 
7 16.3 21.9 24.3 ++ + + + 108.0 32.5 
8 16.2 27.7 35.1 _ + + _ 120.0 43.0 
Mean 13.5 23.9 27.1     110.6 34.4 
^ since baseline 
* BMI , body mass index, calculated as weight in kilograms divided by the height in 
meters2 
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Table 5. Patient laboratory measurements 
 
 
Patient Cholesterol 
(mg/dL) 
LDL-C 
(mg/dL) 
HDL-C 
(mg/dL) 
Triglycerides
(mg/dL) 
Nadir 
CD4+ 
(cells/mm3) 
Recent 
CD4+ 
(cells/mm3) 
1 239 122 53 NA 400 590 
2 226 132 57 189 461 461 
3 196 97 72 546 130 436 
4 158 74 36 240 452 856 
5 166 117 23 146 501 815 
6 229 132 44 118 19 782 
7 210 111 49 252 108 436 
8 182 105 41 413 298 1364 
Mean 201 111 47 272 296 718 
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein. 
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Table 6. Patient antiretroviral therapy duration 
 
  
 Total duration of antiretroviral therapy in years 
 Duration of protease inhibitor therapy in years   
Patient Any 
ART 
Indinavir Ritonavir Saquinavir Nelfinavir Total Stavudine Zidovudine
1 11.0 0 0 ^ 0 ^ 9.0 1.0 
2 7.5 0 0 0 ** ** 5.5 ** 
3 10.5 0 0 4.5 0 4.5 0 10 
4 5.0 0.5 0 0 0 0.5 5.0 0.5 
5 4.5 0 0 0 3.0 3.0 3.0 1.5 
6 5.0 5.0 0 0 0 5.0 0 0 
7 5.5 2.5 3.0 2.5 0 5.0 3.0 2.5 
8 13.0 0 0 1.5 2.5 5.5 1.5 9.0 
Mean 7.8        
Abbreviations: ART, antiretroviral therapy; 
^ There were temporal gaps in this patient’s study visits between 1995 and 2001, so the 
exact duration of his protease inhibitor-based therapy is unknown.   
**Most medication exposure was prior to study enrollment, so duration of receipt of 
some antiretroviral medication is not specified in the research records. 
 
 
 
4.2.4 Comment 
We believe that these patients demonstrate a previously unreported manifestation of 
lipoaccumulation.  We were not able to identify the specific cause. Lipoatrophy has been 
associated with stavudine or zidovudine use, lipoaccumulation and insulin resistance with 
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protease inhibitor use, and hyperlipidemia with any of these therapies. (39-41)  Other possible 
risk factors are HIV disease stage, age, race, and sex. (42)  Since all 8 men had preexisting 
lipoaccumulation of some kind, this type of lipoaccumulation may represent a progression for 
some of the individuals.  None were obese.  Treatment-related etiologic factors were not readily 
apparent, but all had received protease inhibitor-containing HAART. 
Our database has limitations on potentially relevant clinical information. Because we 
have not yet been able to undertake systematic review of all MACS participants for the presence 
of lipoaccumulation, a prevalence estimate cannot yet be reliably ascertained. There is not a 
single objective measure that can be systematically applied to all MACS participants specifically 
to discern this phenomenon. In addition, retrospective analyses do not allow for precise 
measurement of time of onset. Comparative evaluation and prospective observation are needed 
to further characterize this clinical entity.  
4.2.5 Acknowledgement of funding / support 
This work was supported by the National Institute of Allergy and Infectious Diseases, with 
additional supplemental funding from the National Cancer Institute (grants U01-A1-35042, 5-
M01-RR-00052 [GCRC], U01-A1-35043, U01-A1-37984, U01-A1-35039, U01-35040, U01-
A1-37613, and U01-A1-35041. 
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5.0  PREFACE TO THIRD PUBLICATION 
The development of HIV-LS can be disturbing to patients who fear that their HIV-infection may 
become obvious to others. Clinicians within the MACS are aware of anecdotal examples of HIV-
LS negatively impacting quality of life.  Several subjects have reported changes in social 
behaviors as the result of their body habitus changes, including avoidance of swimming and 
sunbathing in public, wearing shorts and sleeveless shirts, and being uncomfortable in many 
everyday situations.  
5.1 SPECIFIC AIM #3 
Specific aim #3, describe quality of life patterns among HIV-infected men with HIV-LS,  is 
addressed in a manuscript originally published in AIDS Patient Care & STDs. Reprint 
permission was granted for inclusion in this doctoral dissertation March 3, 2008. 
 
 
 
 
 
 
 30 
5.2 EFFECTS OF LIPODYSTROPHY ON QUALITY OF LIFE AND DEPRESSION 
IN HIV-INFECTED MEN ON HAART 
 
JL Steel,1 D Landsittel,2 B Calhoun,2 S Wieand, 2 LA Kingsely3 
 
1School of Medicine, University of Pittsburgh, Pittsburgh, PA; 2Graduate School of Public 
Health, University of Pittsburgh, Pittsburgh, PA. 
AIDS PATIENT CARE and STDs 2006;20(8):35-45. 
 
5.2.1 Abstract 
The aim of the study was a prospective assessment of the possible consequences of a diagnosis 
of lipodystrophy on health-related quality of life (HRQL) and depressive symptomatology in 
HIV-seropositive men who have sex with men. A standardized physical assessment for 
lipodystrophy was introduced within a prospective study in April 1999. Over a 2-year follow-up, 
37 HIV-seropositive men who met the criteria for lipodystrophy were longitudinally compared to 
92 HIV-seropositive men without lipodystrophy and 88 HIV-seronegative men on measures of 
HRQL and depression. A series of questionnaires, which included the Medical Outcomes Study 
Short-Form 36 (SF-36) and the Center for Epidemiological Studies-Depression (CES-D), were 
administered to assess HRQL and depression, respectively. SF-36 scores were summarized using 
the mental and physical components; CES-D results were reported as both dichotomous (with or 
with clinical depression) and continuous scores. Neither the mental nor physical components of 
the SF-36 showed any significant differences between patients with lipodystrophy versus HIV-
seropositive patients without lipodystrophy. Similarly, lipodystrophy status was not significantly 
associated with either continuous depression scores or presence of clinical depression. However, 
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consistent with previous results, HIV-seropositive men without lipodystrophy (compared to 
HIV-seronegative men) reported higher scores on both components of the SF-36 scales and both 
categorizations of the CES-D. The results of this study suggest that lipodystrophy does not 
negatively affect HRQL or depression, above and beyond, the diagnosis of HIV infection, 
although the impact of the severity of lipodystrophy on these conditions will require further 
study. 
5.2.2 Introduction 
Since the advent of highly active antiretroviral therapy (HAART), new challenges have been 
encountered by persons infected with HIV and clinicians treating those with HIV infection. 
Lipodystrophy is one of the most profound side effects of antiretroviral therapy and/or long-term 
infection with HIV. Lipodystrophy is characterized as a heterogeneous array of metabolic and 
morphologic changes including central adiposity (truncal fact accumulation), peripheral 
lipoatrophy (loss of subcutaneous fat on the arms and legs), facial lipoatrophy (loss of fat from 
the face), and accumulation of fat on the back of the neck. Metabolic alterations such as 
hyperinsulinemia and hyperlipidemia are often observed in combination with these morphologic 
changes. (43). Although still not known, the metabolic changes are suspected to increase the risk 
for diabetes and coronary heart disease in persons with lipodystrophy. (44, 45)  Lenert and 
colleagues, suggested that the diagnosis of lipodystrophy was associated with 1% greater risk of 
death (46). 
The prevalence of lipodystrophy varies according to the individual rating the bodily 
changes (patient versus physician), demographic variables such as age and gender, and methods 
of measurement (47).  The methods of measuring morphologic changes associated with 
lipodystrophy are not universal and the syndrome appears to be heterogeneous and there 
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continues to be no widely accepted definition. Kingsley has described two separate phenotypes 
associated with lipodystrophy; the first is characterized by moderate to severe subcutaneous fat 
loss in two or more areas (i.e., arms, legs, buttocks or face) and termed peripheral lipoatrophy. 
(15) The second phenotype, mixed lipodystrophy, includes moderate to severe peripheral 
lipoatrophy (as described above) in addition to moderate to severe fat accumulation in the 
abdomen or breasts, with or without additional fat at the back of the neck. The mixed 
lipodystrophy group is therefore a subset of those men with peripheral lipoatrophy. For 
simplicity, men in either group (i.e., having peripheral lipoatrophy with or without mixed 
lipodystrophy) will be subsequently referred to as having lipodystrophy syndrome or HIV-LS. 
Tien and colleagues reported that HIV-infected women were twice as likely to develop 
peripheral and central lipoatrophy compared to HIV-uninfected women. (48). Although 
inconsistent results have been reported, there appears to be a strong correlation between the use 
of protease inhibitors (PIs) and lipodystrophy, however not all persons taking PIs develop 
lipodystrophy and persons who have not taken a PI have reported lipodystrophy. Some studies 
have found that the development of lipodystrophy is associated with lack of response to 
HAART. (15,43)  Others have noted an associated with the use of HAART and low CD4 count. 
Mauss and colleagues reported that the use of stavudine and a CD4 count less than 200 cells per 
microliter was associated with increased risk for lipodystrophy while non-nucleoside reverse 
transcriptase inhibitor (NNRTI) use is related to a reduced risk (43,49). 
Relatively few treatment options have become available for patients suffering from 
lipodystrophy. Treatment with recombinant human growth hormone (rhGH) or testosterone has 
demonstrated some effect at reducing truncal adiposity as well as the fat accumulation on the 
back of the neck. (50)  A recent prospective, randomized trial was reported by Kotler and 
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colleagues and found that the 1 mg daily of rhGH warrants further research for the treatment of 
excess trunk fat. (51) Researchers have also noted that a change from PIs to nevirapine may lead 
to a reversal of symptoms associated with lipodystrophy but this has not been effective in all 
patients. (52,53) Substitution of abacavir for AZT or d4T leads only to small, clinically 
insignificant decreases in lipoatrophy. (54) 
The underlying mechanisms and methods of treatment of lipodystrophy are not well 
understood or established, however, the morphologic and metabolic changes are believed to have 
a significant impairment on the patient's HRQL, particularly the patients' psychological well-
being. As with other diseases, the benefits and consequences of treatment must be weighed. 
HRQL, as well as survival, must be recognized as an important outcome in the treatment of HIV. 
Few studies have been published concerning the effects of lipodystrophy on HRQL or 
reported depressive symptoms in HIV-seropositive patients diagnosed with lipodystrophy (55-
57). Falutz found that of 82 patients with lipodystrophy, 67% described the morphologic and 
metabolic changes as tolerable while 70% of patients reported depressed mood as a result of 
body habitus changes. (55) The facial lipoatrophy appeared to have the greatest impact on 
patients followed by central adiposity (55). Eighty-six percent of patients described the changes 
in their body in a negative way (e.g., "I no longer appear healthy"). Falutz and colleagues' 
investigation, which only included single item measures of HRQL, indicated that the 
development of lipodystrophy may have profound effects on HRQL and mood. (55) 
A second study by Goetzenich and colleagues found that a diagnosis of lipodystrophy 
was correlated with decreased social contact (63%), changes in daily performance (68%), 
changes in sexual functioning (68%), and decreased self-esteem (83%). (56). A detailed analysis 
found that sexuality was most affected by changes in the abdomen and neck while ratings in self-
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esteem were primarily associated with changes in the abdomen. Decreased social contact was 
correlated with changes in the neck, legs, breast while daily performance was related to changes 
in the legs and arms. The strengths of this study were that it identified the various effects of 
lipodystrophy on specific aspects of physical and psychological functioning. Although this study 
provided greater detail in regard to the correlation between body habitus changes and its impact 
on specific areas of HRQL, the study lacked a standardized measure of HRQL and did not 
include a control group. 
In one of the first studies to use standardized measures to assess the effects of 
lipodystrophy on HRQL, women who were HIV-seropositive reported that bodily changes 
associated with lipodystrophy influenced dressing behavior (65%), produced shame (49%), and 
disrupted their sex life (27%). Furthermore, women with breast lipoaccumulation had greater 
psychosocial impairment (57). More recently, Nicholas and colleagues reported that those 
individuals with lower CD4 counts and lipodystrophy reported lower HRQL on the Medical 
Outcomes Study (MOS; SF-36.) (57,58) Nineteen percent of participants reported depressive 
symptoms within the clinical range of the Center for Epidemiological Studies-Depression Scale 
(CES-D), however, no association was found between depressive symptoms and lipodystrophy. 
(58) 
In contrast with these studies, researchers have also found that in HIV-seropositive 
patients treated with HAART, a diagnosis of lipodystrophy was not found to be associated with 
the individuals' attitude about their health condition or their overall well-being. However, 
patients reported that they were about twice as likely to feel recognizable as an HIV-positive 
person by their physical appearance. (59)  It should be noted that this study used single items to 
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assess their attitudes regarding their health condition, well-being, and feelings of being 
recognized as an HIV-seropositive person. 
Depression has also been studied separately in men who have sex with men. A paucity of 
research has been conducted concerning the psychological sequelae of lipodystrophy on patients. 
A study by Tsiodras and colleagues found that patients who were taking psychotropic 
medications (e.g., antidepressants and benzodiazepines) were more likely to have lipodystrophy. 
(60) Given the cross-sectional nature of this study, however, it is not clear if development of 
lipodystrophy led to depression or if the depression, or use of psychotropic medications, 
preceded the diagnosis of lipodystrophy. 
The aims of the present study were to longitudinally investigate associations between 
HRQL and lipodystrophy, and between depression and lipodystrophy. To advance the previous 
research, the present study used standardized instruments and control groups of HIV-seropositive 
patients without lipodystrophy and HIV-seronegative patients. In addition, diagnosis of 
lipodystrophy is based on measurements by a trained physician assistant rather than patient self-
report. 
5.2.3 Materials and methods 
Participants. The participants of this study were drawn from Pittsburgh, Pennsylvania, one of the 
four clinical centers forming the Multicenter AIDS Cohort Study (MACS). The Pittsburgh 
MACS has enrolled 490 HIV-seropositive and 756 HIV-negative men (n = 1252 total) who have 
sex with men (n = 1252). The MACS is an ongoing multicenter prospective cohort study of HIV 
infection in homosexual and bisexual men, of whom most (88%) were enrolled between 1984 
and 1991. Briefly the MACS follows a 6-month visit schedule including detailed interviews, 
medical history, physical examination, and collection of biologic specimens. Further detail can 
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be found in Kaslow et al. (61)  A specific lipodystrophy questionnaire and physical assessment 
were instituted at the 31st MACS visit (April 1, 1999 to September 30, 1999) to study the 
development of HIV-LS in this population. For the purposes of this analysis, the cohort was 
limited to 217 consecutive male patients seen at the Pittsburgh center. Of the 217 men, 129 were 
HIV-seropositive and 88 HIV-seronegative. None of the 88 HIV-seronegative patients had 
lipodystrophy and they are not used in any analyses evaluating the effect of lipodystrophy. 
However, we included these patients to provide a baseline comparison. 
Thirty-seven of the HIV seropositive participants had at least one physical examination 
consistent with lipodystrophy. Lipodystrophy measurements were first collected in April 1999, 
approximately 3 years after HAART became widely available. To maintain the prospective 
nature of the study, the analysis is primarily restricted to all outcomes (SF-36 and CES-D scores) 
from April 1999 to September 2001. Baseline measurements for SF-36 and CES-D scores were 
calculated as the mean score of visits 0 to 26 (i.e., mean score before first initiation of HAART). 
Measurement of lipodystrophy. For the purposes of this study, lipodystrophy was 
assessed by a physician assistant experienced in care of HIV/AIDS patients. The examiner rated 
the patient on two criteria of body change, fat wasting, and fat accumulation. These ratings 
included fat wasting of the face, arms, legs, and buttocks, and fat accumulation of the face, 
abdomen, back of neck, and breasts. Each area was rated according to severity as either (1) none 
(patient does not exhibit any signs of fat maldistribution), (2) mild (mild signs of fat 
maldistribution are noticed by clinician without looking for it), (3) moderate (signs of fat 
maldistribution are noticed by clinician without specifically looking for it or patient may 
complain that current clothing has become tighter), or (4) severe (signs of fat maldistribution 
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easily noted by causal observer). These measurements were then utilized to define lipodystrophy 
status, as previously described. 
HRQ Life. HRQL was measured using the MOS SF-36.  The SF-36 yields a profile of 
eight domains of HRQL including physical, role-physical, bodily pain, general health, vitality, 
social functioning, role-emotional, and mental health. (62,63) Each component score was 
calculated by summing item responses after reversing selected items. Raw scores are then 
linearly transformed to a scale from 0 to 100, with a high score indicating a better HRQL. The 
SF-36 has been widely used and validated. (62) Two summary scores of the SF-36 scores, 
physical and mental functioning, were calculated using the weighted sum of appropriate 
questions, using the principal components derived by Ware. (63) 
Depressive symptomatology. Depressive symptomatology was assessed using the CES-D.  
The scale includes 20 items assessing depressive symptomatology in the previous week. (64)  A 
Likert-type scale is used with ratings from 0 (rarely or none of the time-less than 1 day in the 
past week) to 3 (most of or all of the time-5-7 days in the past week). Total scores range from 0 
to 60, with a score of 16 or more indicating possible clinical depression.   The instrument has 
been demonstrated to be valid and have a high internal consistency and test-retest reliability (8-
week interval r = 0.59). (64)  
Procedures. The participants in the present study were all enrolled prior to the initiation 
of HAART. All participants provided written informed consent prior to their participation in the 
study. Every 6 months after enrollment into the study, participants completed a battery of 
questionnaires, underwent a physical examination, and had extensive laboratory testing 
performed. The physical examination included measurements of fat wasting and fat 
accumulation (as previously described). 
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Data analysis. Statistical analyses were limited to the cohort of 217 men who received at 
least one physical examination for the assessment of lipodystrophy. Both HRQL and depression 
scores were analyzed using a repeated measures analysis with autoregressive correlation (other 
correlation structures were also tested but did not significantly affect results). HIV status alone 
was assessed through comparing seronegative men to the group of seropositive men without 
lipodystrophy, after adjusting for patient age. Within HIV-seropositive men, the significance of 
lipodystrophy status was evaluated after controlling for patient therapy, age and baseline 
response (i.e. mean score for depression or HRQL before first HAART initiation at visit 26). 
After recording CES-D as a dichotomous response (< 16 versus >= 16), analyses were then 
repeated using generalized linear mixed models. The mixed model can be described by the 
following equation, where Y is the observed outcome vector, X[beta] represents the covariate 
values and corresponding model coefficients, and Zu denotes the random effects component 
corresponding the given repeated measures design and correlation structure. 
5.2.4 Equation 
 
The generalized linear model, which is used for modeling repeated binary outcomes follows 
basically the same structure, except that a logistic link function relates the outcome variable to 
the linear combination of fixed and random predictors (on the right hand side of the equation). 
All statistical runs were conducted with SAS 8.01 (SAS Institute, Cary, NC) using either proc 
mixed (for continuous outcomes) or the glmm macro (for the outcome of presence/absence of 
clinical depression). Missing data for individual SF-36 items were imputed using the average 
score across all other questions in that component. The same procedure was used for missing 
data on the CES-D questionnaire. 
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5.2.5 Results 
The demographic characteristics of the participants are described in Table 7. Mean age of 
participants (at visit 31) was 37 with a range of 23 to 69 years. Twenty percent of the men (n = 
32) were below age 30 at visit 31; 73% (n = 116) were age 30 to 50; only 6% (n = 10) were 
above age 50. The majority of men were Caucasian (94%), followed by African American (4%), 
and Native American (1%). Nearly 100% of participants reported at least a high school education 
with 51% completing a 4-year degree. The median viral load (at visit 31, which was the baseline 
for lipodystrophy measurements) was 100 with a range of 80 (or less; values not reported below 
that threshold) to 166,400. The median CD4 count (at visit 31) was 634 with a range of 80 to 
1642. HIV status was known for all 217 men; 129 were HIV-seropositive and 88 were HIV-
seronegative. 
 
Table 7. Demographic and disease-specific characteristics of HIV-seropositive men 
 
 
Age 
Mean 37 
Range 23 – 69 
Ethnicity (%) 
Caucasian 94 
African American 4 
Native American 1 
Other 1 
Education (%) 
High school diploma 99 
College graduate 51 
Postgraduate/professional  
Lipodystrophy phenotype (%) 
Total 54 
Peripheral 40 
Mixed 14 
CD4 Count (Visit 31) 
Median 634 
Range 50 – 1642 
 40 
Table 7 Cont. Demographic and disease-specific characteristics of HIV-seropositive men 
 
Viral load (Visit 31) 
Median 100 
Range <80 – 166, 400 
 
 
Of the HIV-seropositive, 37 (28.7%) were diagnosed with peripheral lipoatrophy during 
at least one visit, while 12 (9.3%) were also diagnosed with the mixed form of lipodystrophy 
during at least one visit. The overall proportion of subjects with peripheral lipoatrophy ranged 
between 9% (at visit 31) to approximately 40% (at visits 34 and 35). The prevalence of mixed 
lipodystrophy was much lower, with a maximum of only 13% of subjects having mixed 
lipodystrophy at visit 35 (April to September 2001; (Table 8). 
 
 
Table 8. Lipodystrophy status within HIV-positive subjects by visit 
 
 
Visit Status Frequency Percent 
Mixed 1 1.0 
Peripheral only 8 7.8 
31 
None 94 91.3 
Mixed 4 4.1 
Peripheral only 15 15.5 
32 
None 78 80.4 
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Table 8 Cont. Lipodystrophy status within HIV-positive subjects by visit 
Visit Status Frequency Percent 
Mixed 11 11.0 
Peripheral only 24 24.0 
33 
None 65 65.0 
Mixed 11 11.7 
Peripheral only 26 27.7 
34 
None 57 60.6 
Mixed 12 12.9 
Peripheral only 25 26.9 
35 
None 56 60.2 
 
HAART was initiated at visit 26, when approximately 20% of patients in this cohort received 
HAART. That percentage steadily increased to over 70% at visit 30, and has remained constant 
at approximately 80% over the last 3 visits (18 months). In contrast, the percentage of people 
receiving mono/combination treatment, or no treatment, has decreased steadily over the last 4 to 
= years (i.e., approximately since visit 25). 
The number of people with at least one severe condition of fat wasting as reported by the 
physician assistant was 4 of 9 of those starting with at least moderate lipodystrophy (44.4%) on 
visit 31. Nine of 19 (47.4%) on visit 32; 21 of 35 (60.0%) on visit 33; 21 of 37 (56.8%) on visit 
34; and 29 of 37 (78.4%) on visit 35 were diagnosed with lipodystrophy. In terms of the 
relationship between lipodystrophy and quality of life outcomes, we again found a very 
inconsistent relationship (quite possibly due to the small sample sizes which are even more 
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limited when restricting the outcome definition to severe conditions). For instance, the mean 
CES-D scores were higher for those with at least one severe condition at visits 31 (14.0 versus 
8.4), 34 (11.7 versus 6.5) and 35 (11.1 versus 8.5), but lower at visits 32 (10.5 versus 12.2) and 
33 (10.5 versus 14.4). This inconsistent relationship was similar in terms of an overall pattern, or 
lack thereof, as compared to the overall analyses of (at least moderate) lipodystrophy presented 
in the results section. 
The prevalence of lipodystrophy was slightly higher in patients on HAART as compared 
to mono-combination therapy. The prevalence for those with peripheral lipoatrophy ranged from 
10% (at visit 31) to 47% (at visits 35) for patients taking HAART; 7%-36% (at visits 31 and 35, 
respectively) for mono/combination therapy; and up to 11% (at visit 35) for patients not taking 
any HIV-related medications. 
Patient therapy (adjusted for age and baseline scores) was not significantly associated with either 
the physical or mental component scores on the SF-36 (p = 0.99 and p = 0.40, respectively). In 
addition, therapy was not significantly associated with either continuous CES-D scores (p = 
0.94) or presence of clinical depression (p = 0.43). Based on these results, therapy was not 
considered in the following models of lipodystrophy status. 
Separate analyses (not shown here) were initially conducted for the peripheral 
lipoatrophy group without mixed lipodystrophy and the mixed lipodystrophy group. Primarily 
because of small sample sizes within the mixed lipodystrophy group (maximum of n = 12 over 
visits 31-35), and since no significant inconsistencies were detected in the relationship between 
these two categorizations and the (HIV-positive) group without lipodystrophy, further analyses 
focused on the peripheral lipoatrophy group (with or without mixed lipodystrophy; maximum of 
n = 37) versus the HIV-positive group without lipodystrophy. These subsequent comparisons 
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will be referred to as the lipodystrophy group versus the (HIV-positive) group without 
lipodystrophy. In all analyses, lipodystrophy (as well as all other variables considered) is 
measured as a time-dependent variable in the repeated measures model. 
For the mental component of the SF-36, scores were not consistently higher or lower in 
the lipodystrophy group (Table 9). Rather, the lipodystrophy group had similar scores at visits 31 
and 32, slightly lower (by less than a standard error) scores at visit 33, and slightly higher scores 
at visits 34-35 (by 1-1.5 standard errors). The HIV-negative group had consistently higher (SF-
36 mental component) scores in almost all cases. 
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Table 9. Mean SF-36 mental and physical component scores by lipodystrophy status 
 
Visit Status Mental Mean (SE) Median 95% CI 
Lipodystrophy + 45.5 (3.0) 46.8 (38.4, 52.5) 
Lipodystrophy - 45.4 (1.2) 49.2 (42.9, 47.8) 
1.5 
HIV -  48.6 (1.2) 52.3 (46.3, 50.9) 
Lipodystrophy + 45.2 (2.9) 50.3 (39.1, 51.3) 
Lipodystrophy - 45.7 (1.4) 50.7 (42.9, 48.6) 
32 
HIV -  48.8 (1.2) 52.2 (46.4, 51.2) 
Lipodystrophy + 44.2 (2.2) 48.6 (39.6, 48.7) 
Lipodystrophy - 46.2 (1.6) 51.1 (43.0, 49.3) 
33 
HIV -  48.4 (1.2) 52.0 (45.9, 50.8) 
Lipodystrophy + 48.3 (1.8) 51.0 (44.6, 52.0) 
Lipodystrophy - 47.0 (1.5) 52.4 (44.0, 50.0) 
34 
HIV -  48.4 (1.3) 52.3 (45.9, 50.9) 
Lipodystrophy + 49.1 (1.8) 52.9 (45.4, 52.9) 
Lipodystrophy - 46.4 (1.8) 52.8 (42.8, 50.0) 
35 
HIV -  48.4 (1.2) 51.5 (45.9, 50.8) 
Visit Status Physical Mean (SE) Median 95% CI 
Lipodystrophy + 47.2 (2.7) 49.5 (40.9, 53.4) 
Lipodystrophy - 51.4 (1.0) 55.4 (49.3, 53.4) 
31 
HIV -  55.2 (0.7) 57.0 (53.7, 56.6) 
Lipodystrophy + 48.4 (2.8) 53.2 (42.5, 54.3) 
Lipodystrophy - 52.5 (0.95) 55.7 (50.6, 54.4) 
32 
HIV -  55.2 (0.8) 57.0 (53.6, 56.7) 
Lipodystrophy + 46.9 (1.9) 49.1 (43.0, 50.9) 
Lipodystrophy - 53.0 (1.0) 55.9 (51.0, 55.0) 
33 
HIV -  55.2 (0.7) 56.8 (53.8, 56.6) 
Lipodystrophy + 48.8 (1.9) 51.6 (45.0, 52.6) 
Lipodystrophy - 54.2 (1.1) 56.9 (52.0, 56.5) 
34 
HIV -  54.5 (0.9) 56.7 (52.7, 56.3) 
Lipodystrophy + 48.9 (1.9) 51.8 (45.0, 52.8) 
Lipodystrophy - 52.7 (1.1) 55.4 (50.5, 55.0) 
35 
HIV -  54.3 (0.9) 56.0 (52.5, 56.0) 
Lipodystrophy + includes peripheral lipoatrophy with or without mixed lipodystrophy; 
Lipodystrophy – includes 
              only HIV patients without lipodystrophy. 
SE, standard error; CI, confidence interval. 
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Regarding the physical component scores, the lipodystrophy group showed more 
consistently decreased levels (Table 9). The mean score for the lipodystrophy group ranged 
between 47 and 49, whereas the group without lipodystrophy had mean scores ranging from 51 
to 54. The HIV-negative group again showed higher mean scores across all time points. 
To evaluate the statistical significance of associations between lipodystrophy and SF-36 
summary scores (mental and physical component summaries), age, and baseline SF-36 summary 
scores (see Materials and Methods section) were entered as covariates in the mixed model. 
Although some consistent patterns were evident for the mean physical component scores, 
lipodystrophy was not significantly associated with either the physical component summary 
score (p = 0.70) or the mental component summary score (p = 0.81). The comparisons between 
the HIV-positive and HIV-negative groups were all highly significant (p < 0.01 for the physical 
component and p = 0.03 for the mental component). 
CES-D scores did not show any consistent association between lipodystrophy and 
depression (Table 10). Both of the HIV-positive groups, with and without lipodystrophy, did 
however show increased depression scores versus the HIV-negative group across most all time 
points. Results of the repeated measures model also indicated that lipodystrophy was not 
significantly associated (after adjusting for age and baseline CES-D) with CES-D scores (p = 
0.55). Further, after categorizing CES-D scores as 16 or greater versus less than 16, 
lipodystrophy was not significantly associated with presence of clinical depression (p = 0.28) 
(Table 11). HIV status alone, however, again led to highly significant results for both the 
continuous (p < 0.01) and dichotomous (p = 0.01) CES-D scores. 
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Table 10. Mean CES-D scores by lipodystrophy status 
 
 
Visit Status Mean (SE) Median 95% CI 
Lipodystrophy + 10.9 (3.1) 8.0 (3.6, 18.1) 
Lipodystrophy - 12.6 (1.2) 10.0 (10.3, 15.0) 
31 
HIV - 8.7 (1.0) 6.0 (6.8, 10.6) 
Lipodystrophy + 11.4 (2.4) 9.0 (6.5, 16.4) 
Lipodystrophy - 11.1 (1.3) 7.5 (8.6, 13.6) 
32 
HIV - 8.4 (1.0) 6.0 (6.4, 10.4) 
Lipodystrophy + 12.3 (2.0) 10.0 (8.2, 16.3) 
Lipodystrophy - 10.9 (1.5) 7.0 (8.0, 13.8) 
33 
HIV - 9.5 (1.1) 6.0 (7.2, 11.7) 
Lipodystrophy + 9.2 (1.6) 6.5 (6.0, 12.3) 
Lipodystrophy - 9.9 (1.4) 6.5 (7.0, 12.8) 
34 
HIV - 9.3 (1.2) 5.0 (6.9, 11.6) 
Lipodystrophy + 10.2 (1.8) 7.4 (6.5, 13.9) 
Lipodystrophy - 11.6 (1.7) 8.0 (8.1, 15.0) 
35 
HIV - 8.8 (1.1) 5.1 (6.7, 11.0) 
Lipodystrophy + includes peripheral lipoatrophy with or without mixed lipodystrophy; Lipodystrophy – includes 
only HIV+ patients without lipodystrophy. 
CES-D, Center for Epidemiological Studies – Depression; SE, standard error; CI, confidence interval. 
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Table 11. Clinical depression by peripheral lipoatrophy status 
 
 
Visit Status CES-D ≥ 16 (%) CES-D < 16 (%) 
Lipodystrophy + 2 (22.2) 7 (77.8) 
Lipodystrophy – 30 (32.3) 63 (67.7) 
31 
Hiv – 17 (21.5) 62 (78.5) 
Lipodystrophy + 3 (16.7) 15 (83.3) 
Lipodystrophy – 26 (33.3) 52 (66.7) 
32 
Hiv – 16 (20.0) 64 (80.0) 
Lipodystrophy + 10 (28.6) 25 (71.4) 
Lipodystrophy – 16 (24.6) 49 (75.4) 
33 
Hiv – 18 (22.8) 61 (77.2) 
Lipodystrophy + 7 (19.4) 29 (80.6) 
Lipodystrophy – 14 (25.0) 42 (75.0) 
34 
Hiv – 18 (23.1) 60 (76.9) 
Lipodystrophy + 8 (22.9) 27 (77.1) 
Lipodystrophy – 16 (29.1) 39 (70.9) 
35 
Hiv – 15 (19.2) 63 (80.8) 
Lipodystrophy + includes peripheral lipoatrophy with or without mixed lipodystrophy; Lipodystrophy – includes 
only HIV+ patients without lipodystrophy. 
CES-D, Center for Epidemiological Studies – Depression. 
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5.2.6 Discussion 
Previous research has found, when using nonstandardized questionnaires, that lipodystrophy is 
reported to affect HRQL, particularly in the area of interpersonal and sexual functioning. (66) 
Goetzenich and colleagues reported that a diagnosis of lipodystrophy was associated with 
decreased social contact, changes in daily performance, problems with sexual relations, and 
decreased self-esteem. (56) In contrast, we found that, among HIV-seropositive participants, a 
diagnosis of lipodystrophy, in general, was not found to be associated with decreased HRQL. 
(48,56)  Although it was expected that patients with lipodystrophy would have a lower HRQL, 
particularly on scales measuring social and emotional well-being, 7,15 no significant differences 
were identified in either the mental or physical summary scores measured by the SF-36. 
Falutz and colleagues 14 found that approximately 70% of patients with lipodystrophy 
reported some symptoms of depression; however a standardized instrument to measure 
depression or clinical interview were not used. (55) Therefore, it is difficult to ascertain how 
severely the participants' mood was affected by the diagnosis of lipodystrophy. The results of the 
present study found that lipodystrophy, over and above a diagnosis of HIV, was not associated 
with elevated scores on the CES-D. Although the number of participants with lipodystrophy in 
this sample was relatively small, the use of a standardized instrument to assess depressive 
symptoms provided greater validity and reliability in the measure of depressive symptoms in 
these patients. 
Prior research has demonstrated that patients who reported facial atrophy were three 
times more likely to seek treatment than patients with other types of lipodystrophy. (57).  Post 
hoc analyses revealed that the presence of lipodystrophy in various areas of the body (e.g., face, 
trunk) was not found to be related to decrements in HRQL or mood. 
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The prevalence of lipodystrophy in this study was consistent with previous studies 
assessing body habitus changes in HIV-seropositive patients. At the last patient visit recorded 
(April to September 2001), approximately 47% of patients taking HAART met the criteria for 
lipodystrophy. Dukers and colleagues found a similar prevalence in which approximately 50% of 
patients were self-diagnosed. (66) A strength of the present study is that the diagnosis of 
lipodystrophy was made by a trained physician assistant. 
Although no previous study has been conducted specifically addressing the effects of 
lipodystrophy on mood, a study by Tsiodras and colleagues found that patients who were taking 
psychotropic medications (e.g., antidepressants and benzodiazapines) were more likely to have 
lipodystrophy than those who have not been diagnosed with lipodystrophy. (60) If the same is 
true for the present study, the lack of differences in reported depressive symptomatology may be 
a result of the depression that was treated in patients with lipodystrophy. 
Although MACS does offer a unique environment for studying the effects of 
lipodystrophy, the study was somewhat limited by a relatively small sample size. The mixed 
lipodystrophy group was particularly small (n = 12). Some of the analyses showed a trend toward 
some effect, particularly in the case of mental component scores (worse in the lipodystrophy 
group) and clinical depression (better in the lipodystrophy group than the other HIV-
seropositives). Our follow-up of persons receiving HAART after lipodystrophy was also limited. 
It would be premature to conclude that the effects of lipodystrophy on HRQL would remain 
minimal beyond our observation period, as both lipodystrophy severity and HAART-associated 
metabolic toxicities increase. Despite this caution, it is encouraging that the minimal changes in 
HRQL reported herein were observed in this HAART-experienced population. The results of the 
study suggest that, although the adverse effects of changes in body habitus as a result of HAART 
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are profound, as a whole, the symptoms do not significantly effect HRQL or mood (as measured 
with the SF-36 and CES-D) above and beyond that of a diagnosis of HIV. 
It may be that the differences in HRQL and mood between people diagnosed with 
lipodystrophy and those without cannot be detected statistically. Further research concerning 
clinically meaningful differences between scores on the SF-36 as well as the CES-D should be 
performed. Although not the goal of this study, previous research has demonstrated that although 
lipodystrophy may not affect HRQL or mood, symptoms of lipodystrophy are associated with 
decreased medication adherence.(67)  As a result of decreased adherence to medication 
regimens, patients who develop lipodystrophy may experience increased viral loads, 
opportunistic infections, and possibly increased mortality compared to patients without 
lipodystrophy. The discontinuation of HAART secondary to lipodystrophy warrants further 
research, particularly if it is associated with increased morbidity and mortality. Furthermore, 
although the HRQL instruments may not detect statistically significant differences in HRQL and 
mood in people with lipodystrophy. 
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6.0  PREFACE TO FOURTH PUBLICATION 
HIV-infection can damage the myocardium, endocardium and pleura. Autran and colleagues first 
described a case of pericardial Kaposi’s sarcoma in a patient with AIDS in 1983. (68)  Since 
then, clinicians have gained a comprehensive understanding of the many cardiac manifestations 
of HIV-infection and AIDS.  These include pericardial effusions, endocardititis, dilated 
cardiomyopathy, and pulmonary hypertension.  While HAART, has decrease the prevalence of 
cardiac diseases caused by opportunistic infections and malnutrition, the increasing prevalence of 
antiretroviral-associated metabolic abnormalities have raised concerns about potential 
atherosclerosis mediated cardiac morbidity and mortality. Several cases of premature 
atherosclerosis and cardiac events have been described among patients treated for HIV-infections 
among patients with and without traditional risk factors. (10,12,69)  Thus, the relationship 
between metabolic toxicities, HAART therapy and increased cardiovascular risk has become an 
area of intense research, especially as increasing numbers of patients face years of antiretroviral 
therapy.   
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6.1 PATHOGENESIS OF CORONARY ARTERY DISEASE 
6.1.1 Introduction 
Atherosclerotic disease occurs in the high-pressure coronary vasculature because of defects in 
the endothelium. The initiating abnormality is most often sub-intimal accumulation of plaques. 
These plaques are likely the result of high levels of circulating low-density lipoproteins (LDL).  
Associated with the recruitment of monocytes to the area, these accumulated lipid particles 
undergo oxidative changes and are then referred to as foam cells, which reflects the foamy 
appearance of the cytoplasm.  The sub-intimal defects continue to enlarge mainly due to a 
prolonged inflammatory response and develop into fatty streaks.  Over time, these fatty streaks 
become calcified and have the potential to cause stenosis of the vessel if a large enough area is 
involved. The degree of calcification usually correlates with advancing lesions.  (70) If the 
stenosis develops gradually, arteriogenesis occurs and collateral vessels are used to perfuse the 
area of the myocardium affected by the stenosis. However, if a thrombus forms in an existing 
stenotic vessel, the collateral arteries are often inadequate to maintain normal cardiac perfusion.  
In addition to forming a stenotic area, the plaques can rupture. Rupture of vulnerable plaques 
leading to coronary thrombosis accounts for most acute coronary syndromes.  The rupture 
exposes the endothelial cells to the oxidized LDL and inflammatory cells.  Increased levels of 
platelet derived growth factor (from infiltrating macrophages) and plasminogen activator 
inhibitor (from oxidized LDL) cause clot formation in the vasculature and propagate thrombus 
formation.  In normal vasculature, the appropriate response is vasodilation of the vessel in order 
to continue to perfuse the more distal area.  However, oxidized LDL has been shown to induce 
the expression of endothelin which inhibits the vasodilation.  The result is a thrombus in a 
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constricted vessel which may lead to a partial or totally occlusion.  When a coronary artery 
becomes partially or totally occluded, myocardial ischemia becomes evident. 
6.1.2 Risk Factors for coronary artery disease 
Atherosclerotic disease of the coronary arteries and peripheral vasculature remains the leading 
cause of death in the United States and worldwide.  Given the increasing prevalence of coronary 
artery disease (CAD), efforts have been put forth toward primary, secondary and tertiary 
prevention. Through post-mortem examination of young adults, it is now widely understood that 
the process of atherosclerosis begins decades before the disease becomes clinically evident.  The 
risk factors for coronary artery disease in the general population have been well documented and 
include, cigarette smoking, hypertension, male age > 45 years, female age > 55 years (or 
postmenopausal without estrogen replacement), and first degree family history of premature 
coronary artery disease.  In response to the epidemiologic studies that have illustrated the 
relationship between hyperlipidemia and coronary artery disease, the National Cholesterol 
Education Program (NCEP) has identified additional risk factors for the development of CAD. 
(28)  These risk factors include HDL < 40 mg/dL, total cholesterol (TC) > 200 mg/dL, and LDL 
>130 mg/dL. The most recent NCEP III guidelines omit diabetes and other forms of 
atherosclerotic disease (peripheral vascular disease, abdominal aortic aneurysm and symptomatic 
carotid artery disease) as risk factors, and now consider them as coronary heart disease 
equivalents. (28) 
Primary prevention for coronary artery disease includes strategies that are initiated before 
the pathogenesis has begun.  For example, programs which discourage children from ever 
starting to smoke, and encouraging a physically active lifestyle would be considered primary 
prevention for coronary artery disease.  Secondary prevention includes attempts to minimize 
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complications or clinical outcomes from disease once it has been diagnosed.  For example, once 
an individual is found to have coronary artery disease and hyperlipidemia, lipid lowering 
medications should be prescribed.  Finally, tertiary prevention involves attempts to minimize 
debilitation or death from disease and may involve surgical bypass grafting for those with severe 
or multi-vessel coronary artery disease.  In order to reduce the risk of major coronary events, 
efforts involving diet modification, aerobic exercise and weight reduction are often the first to be 
instituted once hyperlipidemia is diagnosed.  If sub-optimal results are obtained, or if the patient 
already adheres to these practices and maintains normal body weight, pharmacologic 
interventions may be necessary.   
6.1.3 Methods of detecting coronary artery disease 
Coronary artery disease cannot be detected during a routine physical, although, the complications 
of risk factors for CAD are easily detected during a thorough examination.  For example, 
hypertensive patients may develop an additional heart sound, S4, arterial bruits, and/or  
fundoscopic changes.  Diabetic patients may develop peripheral neuropathy, renal insufficiency, 
superficial ulcerations, and fundoscopic changes.   When such findings are present, the clinician 
has compelling evidence that the disease (HTN, DM, etc) has progressed to the point of end-
organ damage which may include atherosclerosis of the coronary, cerebrovascular and peripheral 
vascular beds.  There are no blood tests that are confirmatory for coronary artery disease.   Serial 
cardiac enzymes and troponin I levels are helpful in establishing the diagnosis of acute 
myocardial infarction, however, they offer no value in the progression or long-term follow-up of 
coronary artery disease.  Lipid levels and C-reactive protein appear to be the only laboratory tests 
of value in terms of disease surveillance.  C-reactive protein is an inflammatory marker and 
elevated levels are associated with an increased risk of coronary events.    The addition of C-
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reactive protein to standard lipid testing panels has been shown to improve outcome prediction in 
the primary prevention of acute coronary events.  Apolipoprotein B levels represent the protein 
component of the LDL molecules and serum levels can easily be measured.  Apolipoprotein B 
levels are not traditionally used as a screening tool, although, they have been used in clinical 
research trials which attempt to identify easily measurable surrogates for CAD risk. 
Similar to most other medical conditions, the first step in the evaluation process for 
coronary artery disease involves non-invasive studies.  The most common and inexpensive one is 
electrocardiography (EKG). During acute myocardial infarction, characteristic EKG findings 
include inverted T-waves, and ST-segment changes.  Typically, ST-segment depression indicates 
subendocardial ischemia while ST-segment elevation is consistent with the more severe 
transmural ischemia. Findings on EKG can also suggest conditions resulting from CAD such as 
conduction defects or an old infarction. Mortality from acute myocardial infarction usually 
occurs when infarction leads to ventricular tachycardia or ventricular fibrillation. 
Electrocardiography will not provide information regarding the presence/absence of subclinical 
atherosclerosis.  Chest X-rays are of only limited value in the work-up of coronary artery disease 
and most likely show only subsequent congestive heart failure or cardiomegaly.  
Echocardiography is a non-invasive ultrasound of the heart.  It is most helpful in the evaluation 
of valvular deformities or vegetations, ventricular size and function and the presence of atrial 
thrombi, or pericardial effusions.  Since the coronary arteries are not adequately visualized, this 
testing offers no value for screening for or quantifying the degree of coronary artery disease. 
Magnetic resonance imaging (MRI) has many functions and has been traditionally used for 
imaging soft-tissue injuries to the knee or hip.  MRI does not appear to be a reliable tool for 
assessing and quantifying CAD because the cardiac and respiratory motions distort the images 
 56 
and makes interpretation difficult and unreliable.  However, MR angiography (MRA) does have 
a role in detecting peripheral and cerebral atherosclerosis. 
In order to most accurately assess the true severity of atherosclerotic lesions medical 
imaging of the vasculature is necessary. Typically, patients with angina experience pain only 
with physical activity, and remain symptom free at rest.  If an individual has a history of 
intermittent chest pain and is found to have abnormalities on EKG testing, the next step in 
evaluation is cardiac stress testing. During this evaluation patients are exercised, typically on a 
treadmill, in order to stress the heart and increase cardiac demands.  Any signs or symptoms 
consistent with cardiac disease during the procedure are documented.  While the test is being 
performed, the individual is evaluated for respiratory effort, heart rate, blood pressure and is also 
monitored by cardiac leads.  This test is considered positive when symptoms of chest pain, 
diaphoresis or hypotension occur, or when there are EKG changes consistent with cardiac 
ischemia.  As a second component of this examination, cardiac scanning with thallium-201 for 
myocardial perfusion is performed.  For those individuals in which physical activity is not 
possible, (such as those with concurrent pulmonary disease or other conditions which limit their 
capacity for activity), the heart rate can be elevated with persantine or adenosine.  Uptake of 
these pharmacologic agents by the myocardium is directly proportional to the to coronary blood 
flow.  By using adenosine, (or persantine) as an adjunct to thallium-210, areas of the 
myocardium which are perfused by vessels with stenotic lesions can be identified.  If significant 
coronary artery disease is suspected from the findings on the stress (or adenosine) thallium study, 
the next step is cardiac catheterization.  This extremely reliable test is very common and allows 
for immediate catheter assisted intervention in some instances.  The procedure involves 
cannulating the femoral artery and advancing the catheter to the heart where a contrast material 
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is infused into the coronary arterial circulation.  Images of the coronary vasculature can then be 
reviewed for evidence of arterial stenosis and perfusion defects.  Due to the cost and 
invasiveness of the procedure, this study is not performed as screening in asymptomatic 
individuals.  When CAD is documented, treatment would depend on the degree or severity of the 
disease.  Conservative treatment may consist only of medication with stent placement being 
recommended for more significant disease.  For those with multi-vessel disease, coronary artery 
bypass grafting with vein grafts may be necessary.  These surgical procedures are not curative 
since patients may develop progression of disease in native vessels and/or develop stenotic 
lesions in the grafted vessels. 
Flouroscopy can be used to detect calcification in coronary arteries. The utility of 
fluoroscopy is greatest when moderate to large calcifications are present and the reliability in 
detecting smaller areas of calcification is less. (70) Additionally, large body-habitus makes 
determining coronary calcium via fluoroscopy technically difficult. (70)  
6.1.4 Electron beam computed tomography 
Coronary artery scanning by electron beam tomography (EBCT) has been shown to 
noninvasively and accurately detect and quantify the degree of calcified atherosclerotic plaque. 
(71,72) It is ideal for screening asymptomatic patients who may be at risk for future cardiac 
events based on risk factors such as family history.   .  
To perform the test, the patient is positioned comfortably in the supine position.  Three 
electrode patches are placed on the inferior-anterior chest and an EKG tracing is obtained.  The 
participant is positioned within the gantry with arms over the head and resting comfortably on 
the armrest.  The participant is asked to hold a breath while the scanner passes from the 
shoulders to the hips. The patient must hold his breath each time the scanner is operated.  The 
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first image is used for calibrating the scanner to the diameter of the chest, subsequent images are 
obtained of the entire heart, taking a cross-sectional image every 3 mm.  The images are obtained 
during the diastolic phase of the cardiac cycle, one image during each heart beat which is 
confirmed with the EKG tracing.  The scan also images the aorta from the aortic arch to the iliac 
bifurcation and cross-sectional images are taken every 6 mm. 
Based on these images, a calcium score can be calculated for each region of interest.  The 
calcium score is generated using a Base Value Region of Interest computer program.  This 
program extracts all pixels above 130 Hounsfield units within an operator-defined region 
measuring 3 mm of thickness.  All pixels greater than 130 Hounsfield units and larger than 1 mm 
within the coronary arteries are considered to be calcium.  A calcium score is then calculated by 
multiplying the area of all significant pixels by a grade number one, two, three, or four indicative 
of the peak CT number.  The individual region-of-interest scores are then summed for a total 
coronary artery calcium score.  The same procedure is used for the aorta.  Because calcium is an 
early feature of atherosclerotic-plaque formation, measurement of coronary calcium correlates 
with the extent of atherosclerosis.  High calcium scores have good sensitivity for coronary artery 
calcification, ranging from 80-90%, but low specificity, ranging from 40-60%.  The total calcium 
volume score can predict future cardiac events.  Calcification of arteries occurs only as a 
consequence of atherosclerosis.  The degree of calcification correlates with hisotomorphometric 
measurements of calcium crystals.  The radiation exposure to the patient during this study is 
minimal.  Generally, external radiation exposure is described as either a dose for a particular 
body region, i.e., the skin the radiation passes through and exposure to the entire body.  The dose 
of radiation to the patient during an EBCT is approximately 0.8 rads to the chest and 2.5 rads to 
the abdomen.  This represents less than 2% of the radiation exposure limit set by the federal 
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regulations (50 rads) to any single organ or tissue allowed for radiation workers per year.  There 
is no minimum level of radiation exposure that is recognized as being totally free of the risk of 
causing cellular abnormalities.  The greatest advantages of this test are that it’s non-invasive and 
that it takes only twenty minutes to properly position the patient, connect the EKG censors and 
complete the scanning.  Screening patients with EBCT is convenient since there is no need for 
intravenous access, fluids or contrast material.  
Coronary calcium scores have been archived for thousands of asymptomatic men and 
women allowing for the creation of a database of “normal values” based on age.(73)  There are 
scores (age and gender stratified) which are believed to have clinical significance.  (73)  The 
development and progression of coronary atherosclerosis is gender dependent. (72). The cutoffs 
most often used are calcium scores of 0, <10, >10<100, >100 indicating no, low, intermediate 
and high risk for future cardiac events.  Quintile scores have been determined for additional 
stratification of risk. (73)  For example, a calcium score of 100 is at the 50th percentile for those 
at age 60, and at the 25th percentile for those who are 50 years old. (72) 
The most significant limitation to EBCT is the correlation between coronary calcification 
and luminal narrowing.  Essentially, calcium may be present which will lead to a high calcium 
score, but if the calcium is distributed circumferentially, the vessel lumen may not be 
significantly compromised.  (72).  Additionally, vulnerable plaques, frequently don’t contain any 
calcium suggesting that a vulnerable plaque may not be detected via EBCT. (72) EBCT is not 
available to patients without the referral of a provider, is relatively expensive ($450) and not 
usually paid for by most third-party payers.    
Women who are premenopausal have lower coronary calcium scores when compared to 
their male counterparts.  Below the age of 50, it is uncommon to find coronary calcium scores 
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>10 in women, whereas 25% of men in the general public below the age of 50 years have scores 
> 10. (73) Women aged 50-59 continue to have scores significantly lower than men of the same 
age. Women aged 60-69 typically have scores similar to men who are 10 years younger.  EBCT 
utilization is of greatest value among older, asymptomatic individuals. (72)   
Both the American Heart Association and the American College of Cardiology publicly 
supported eight points of the 1996 Expert consensus on EBCT which include:  
1. “A negative EBCT test makes the presence of atherosclerotic plaque, including 
unstable plaque very unlikely. 
2. A negative test is highly unlikely in the presence of significant luminal obstructive 
disease. 
3. Negative tests occur in the majority of patients who have angiographically normal 
coronary arteries. 
4. A negative test may be consistent with a low risk of a cardiovascular event in the next 
2-5 years. 
5. A positive EBCT confirms the presence of a coronary atherosclerotic plaque. 
6. The greater the amount of calcium, the greater the likelihood of occlusive CAD, but 
there is not a 1-to-1 relationship, and findings may not be site specific. 
7. The total amount of calcium correlates best with the total amount of atherosclerotic 
plaque, although the true “plaque burden” is underestimated. 
8. A high calcium score may be consistent with moderate to high risk of a 
cardiovascular event within the next 2 to 5 years.” (72)   
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6.1.5 Cardiac disease and HIV-infection 
Concerns about HAART-related atherosclerotic complications were amplified by initial results 
from the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study published in 
2003, in which the authors concluded that the “the incidence of myocardial infarction increased 
with longer exposure to combination antiretroviral therapy” (69). DAD was an international 
collaboration that prospectively followed 23,437 HIV-infected subjects from Australia, Europe 
and the United States from December 1999 through April 2001. The study endpoint was the 
occurrence of a myocardial infarction (MI) during the observation window which lasted through 
February 2005.  During this period, 93.6% of study participants were taking antiretroviral 
medications for a median of 6.9 years. The median exposure to protease inhibitors specifically 
was 4.0 years.(69)  
MI was documented in 345 patients yielding an incidence of 3.65 per 1000 person-years 
and almost 1/3 of these (29.3%) were fatal myocardial. Among those suffering a fatal MI,   
median protease inhibitor exposure was 3.7 years.  The incidence of MI or other ischemic 
vascular event increased directly with antiretroviral exposure, with a relative risk of 1.26 per 
additional year of therapy (95% confidence interval, CI, 1.12-1.41, p<0.001).  (74) Risk 
increased in the presence of traditional cardiac risk factors such as older age, cigarette smoking, 
male sex, elevated serum cholesterol, elevated triglycerides and diabetes mellitus. Subsequent 
analysis determined that both protease inhibitors and non-nucleoside reverse transcriptase 
inhibitors increased risk with an incidence of 5.77 MI per 1000 person-years. (75) 
One of the largest American studies, the HIV Outpatient Study (HOPS) reported an 
increased odds ratio for MI of 4.92 among those receiving protease inhibitors even after 
adjusting for other risks such as age, sex, cigarette smoking, hypertension and dyslipidemia.(76) 
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An alternative to documenting cardiac events is to document the development of 
subclinical atherosclerosis via EBCT in a cohort of HIV-infected men taking HAART.  Three 
cross-sectional studies have investigated prevalence of coronary artery calcification (CAC) via 
EBCT among HIV-infected subjects.  (77-79) Talwani, et al compared CAC scores among HIV-
infected men older than age 40 years without a history of treated hyperlipidemia or coronary 
artery disease to HIV-negative age and race-matched controls to HIV-negative age, and race 
matched male controls. (77) Cases (n=60) included both HAART experienced and naïve 
subjects.  Among HAART treated participants, the treatment duration was 25.9 months (range 6-
61 months).  CAC scores exceeding 0 for 4 coronary vessels were detected in 33% of cases and 
39% of controls (p=0.26).  Clinically significant CAC scores, defined as CAC total score for 4 
vessels exceeding the 75th percentile, were documented in 18% of cases and 17% of controls. 
(77)  Traditional risk factors predicted CAC in both cases and controls.(77) 
Robinson  and colleagues documented a higher proportion of  subclinical atherosclerosis 
defined as increased coronary artery calcium, among treated HIV-infected men aged 30-60 years 
(n=27, mean age: 43.5) compared with HIV-negative age-matched controls (n=81). (78) 
Specifically, a higher proportion of HIV-infected men had CAC scores exceeding the 90th 
percentile compared to HIV-negative controls (p=.034).  An important caveat, however, was that 
in this study, traditional atherosclerosis risk factors were not controlled for or matched. For 
example, nearly twice as many cases (81.5%) reported a smoking history compared to controls 
(41.7%). (78) 
Lai et al attempted to document the effects specifically of protease inhibitors on lipid 
profiles, red blood cell indices, C-reactive protein levels, and coronary calcification among 98 
HIV-infected African-American men and women. (79)  Participants included both protease 
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inhibitor-treated patients (n-55, average age 39.3± 4.5 years) and those who were not (n=43, 
average age 37.8 ± 5.1years).  Eighty-four percent of all subjects were current smokers.  The 
only statistically significant finding with regard to coronary artery calcification was a small 
difference in the proportion of total calcium volume scores that exceeded 5 among non –PI users 
compared to users of nelfinavir (p<0.05) and  ritonavir (p<0.05). (79)  
To date, no longitudinal studies have evaluated coronary artery calcification among 
individuals treated for HIV-infection.   
6.2 SPECIFIC AIM  #4 
Specific Aim #4, to document prevalence of CAC via EBCT among a cohort of HIV-infected 
men and document risk factors for progression of CAC, is addressed in a manuscript entitled, 
“Progression of subclinical coronary atherosclerosis (CAC) in HIV-infected men using highly 
active antiretroviral therapy (HAART)”. 
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6.3.1 Introduction 
Highly active antiretroviral therapy (HAART) has reduced AIDS incidence and mortality and 
has dramatically prolonged life expectancy of those infected with the human immunodeficiency 
virus (HIV). Despite the efficacy of HAART to suppress viral replication and promote immune 
reconstitution, HAART has been associated with a constellation of potentially pro-atherogenic 
metabolic derangements including hypertriglyceridemia (3,4,80-83), hyperglycemia (84), insulin 
resistance (85-89), and central obesity. (15,89)  The long-term effects of these changes in HIV-
infected individuals have not been fully explored, but in the general population those conditions 
are associated with microvascular and macrovascular changes resulting in atherosclerosis and 
impaired endothelial function. (10) 
 Several reports of myocardial infarction (MI) among protease inhibitor (PI)-treated 
patients without known coronary artery disease (CAD) risk factors were suggestive of increased 
atherosclerosis in HIV-infected patients. (90,91) . The HIV Outpatient Study (HOPS), one of the 
largest American studies, showed that the risk for MI was increased nearly five-fold among those 
with exposure to PIs, even after adjustment for age, sex, cigarette smoking, hypertension and 
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dyslipidemia. (76)  The International Prospective Study of Cardiovascular Risk and 
Antiretroviral Therapy – Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) Study 
reported an incidence of myocardial infarction among those not exposed to protease inhibitors as 
1.53 per 1000 person-years and an incidence of MI among those treated with protease inhibitors 
of 6.01 per 1000 person-years (75). Investigators noted the incidence of MI increased 
proportionally with the duration of exposure to protease inhibitors, with an increased relative risk 
of 1.16 (95% CI, 1.10-1.23) per additional year of therapy. (75)   
Coronary artery calcification (CAC) assessed by electron beam tomography (EBCT) can 
provide a sensitive and replicable measure of subclinical coronary atherosclerosis that strongly 
predicts subsequent cardiovascular disease. (71,72)  EBT is non-invasive, and can detect CAC in 
the absence of associated vascular stenosis or occlusion. Therefore, it can detect subclinical 
disease and is ideal for screening asymptomatic patients. No studies have prospectively assessed 
CAC in HIV-infected patients treated with HAART. The purpose of this study was to examine 
risk factors for progression of CAC among HIV-infected men treated with HAART over an 
approximate three year period. 
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6.3.2 Subjects 
Study participants were recruited from those participating in the Multicenter AIDS Cohort Study 
(MACS) at the University of Pittsburgh Graduate School of Public Health site. The MACS 
rationale and design has been described elsewhere. (61)  Briefly, the study began in 1984 to 
evaluate the natural history of HIV-infection among gay and bisexual men.  The study 
population includes both HIV-positive and HIV-negative men.  Participants are seen every six 
months for completion of questionnaires (demographics, health and sexual behaviors, medical 
diagnoses and health care utilization) physical examination, and laboratory evaluation, including 
T-lymphocyte subset analysis, HIV RNA testing, metabolic and lipid testing.    
  Two hundred and twelve men completed a clinic visit between October and March 2001; 
117 of whom were HIV-infected.  Of the 117 potential participants for this substudy, 80 (68.3%) 
were enrolled. Eligibility criteria included infection with HIV, age > 35 years, negative personal 
history of CAD, and ability to provide written consent.  Those not enrolled included men who 
had moved away (n=11), those that could not be contacted by phone (n=9), those with work 
conflicts that did not permit participation (n=8), those who declined participation (n=3), and 
those who did not meet eligibility criteria due to age (n=2), terminal illness (n=1), or preexistent 
CAD (n=3). The study was approved by the Institutional Review Board at the University of 
Pittsburgh and all participants gave written consent.  
6.3.3 Data collection 
Data regarding cardiovascular risks factors, including personal smoking history and family 
history of first-degree male relatives with CAD was elicited through self-administered 
questionnaire and chart review. Self-reported medication histories were used to determine 
participants’ use of lipid-lowering agents and to determine cumulative exposure to HAART.  For 
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the purpose of this study, HAART was defined as a regimen consisting of two nucleoside reverse 
transcriptase inhibitors and a protease inhibitor or two nucleoside reverse transcriptase inhibitors 
and a non-nucleoside reverse transcriptase inhibitor.  
 Diagnostic testing was performed upon enrollment and included fasting lipid testing or, 
for those unable or unwilling to fast, LDL-direct determination. Dyslipidemia was defined as 
total cholesterol > 240 mg/dL, high density lipoprotein (HDL) < 40 mg/dL, low density 
lipoprotein (LDL) > 160 mg/dL, or triglycerides > 200mg/dL.   
 High resolution, non-contrast electron beam tomography (EBCT) images of the heart, 
coronary arteries, and abdominal aorta were obtained both upon enrollment and at a median 
follow-up of 2.7 years utilizing an Imatron C-150 scanner. Coronary artery calcium scoring was 
performed according to standard protocol. Total CAC scores were generated using a Base Value 
Region of Interest computer program and incorporating the area and grade of calcification.  All 
results were reviewed and interpreted by the same attending cardiologist who has expertise in 
this modality.   
6.3.4 Statistical considerations 
Summary statistics were determined for all variables of interest.  Statistical differences in 
baseline characteristics, baseline lipid testing, and the use of lipid-lowering medications across 
(the three) categories of baseline CAC scores were assessed via the Kruskal-Wallis test 
(continuous variables) or chi-square test (categorical variables).  The Kruskal-Wallis test was 
used in favor of the analysis of variance since some of the distributions were moderately to 
highly skewed.  Statistical differences in characteristics of progressors versus non-progressors 
were assessed using the Wilcoxin rank-sum test (continuous variables) or chi-square test 
(categorical variables).  Relationships between each factor and progression of CAC were 
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assessed via logistic regression, where progression of CAC was defined as a 1.5 increase of 
baseline CAC.  For purposes of calculating the ratio of follow-up to baseline CAC, a value of 0.1 
was imputed when the baseline was zero (since any change divided by zero would be undefined).  
The logistic model was used to estimate the odds ratio for each factor, initially without 
adjustment for other factors.  All variables which showed at least marginal significance (i.e. 
p<0.20) with progression were included in the multivariate model. 
6.3.5 Results 
Characteristics of Study Population. All participants were HIV-infected men.  At baseline, the 
median age of participants was 44.7 years (inter-quartile (IQ) range 42.2, 49.8 years).  All but 
two participants were Caucasian (two African-American) and thirty-seven men (46.2%) were 
current or ex-smokers.  Median CD4+ cell count was 619 cells/mm3; median HIV RNA was < 50 
cells / mm3.  Seventy-nine (98.8%) were taking HAART at baseline.  The only subject not 
treated with HAART upon enrollment started nine months later. At baseline, the median duration 
of HAART was 5.01 years (IQ range 3.95, 5.68 years).  Subjects were asked to identify the 
presence of CAD in first-degree relatives, with the majority denying such history. 
Baseline Data. Of the 80 participants, 38 (47.5%) had a baseline total CAC score of zero.  
Nineteen (23.7%) had a CAC between 0 and 10, and 23 had CAC scores greater than 10.  Only 
five individuals (6.2%) had CAC scores in excess of 100. Characteristics of study population are 
stratified by baseline CAC score in Table 12.  The aortic calcium volume scores were highly 
skewed with a median of 15 and IQ range of 0.0, 156.5 (total range 0.0, 5612). The highest 
median aorta calcium score was seen in the group with CAC scores >10.  Sixty percent of 23 
subjects with CAC scores exceeding 10 were either current or ex-smokers; this was the highest 
proportion of smokers among the three groups stratified by CAC scores (0, <10, >10).  
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Serum lipid results at baseline are provided in Table X.  Sixty-three participants had 
dyslipidemia as defined by elevated lipids or by the use of one or more lipid-lowering 
medications at baseline.  The median total cholesterol was 202 mg/dL (IQ range 187.3, 239.3 
mg/dL); 20 (25%) participants had levels in excess of 240 mg/dL. The median HDL was 39.6 
mg/dL (IQ range 33.5, 45.6 mg/dL); 41 (51.2%) had levels lower than < 40 mg/dL.  LDL-C was 
determined for 53 participants and the median level was 114.5 mg/dL.  LDL-D was determined 
for 19 participants and the median level was 119mg/dL.  Seventeen men had an LDL level >160 
mg/dL.  Among the sixty-five participants who had triglyceride levels measured, the median was 
202 mg/dL (IQ range 118, 326 mg/dL).  Serum triglyceride levels exceeded 400 mg/dL in 12 
men including three men with extreme hypertriglyceridemia, defined as a triglyceride level 
greater than 1000 mg/dL. At baseline, twenty-two participants (27.5%) were taking lipid-
lowering medications; six of these were taking 2 medications. Specific medications included: 
HMG-CoA reductase inhibitor (n=14; atorvostatin was used by 12/14), fibrate (n=6), niacin 
(n=1) and one was unspecified.  The use of lipid-lowering medication was highest among those 
in the highest CAC category (43.4%).  (Table 13) 
Follow Up Data.  After a median follow up time of 2.7 years, 73/80 (91.2%) of study 
participants underwent repeat lipid testing and EBT assessment.  Follow up data were not 
available for seven participants due to death (N=4, all from non-cardiac causes), study 
withdrawal (n=1) and loss to follow up (n=2).   
Follow-up laboratory testing revealed a median HIV RNA < 50 cells/mm3 and a median 
CD4+ cell count of 590 cells/mm3.   
At follow-up 36/73 (49.3%) had CAC score exceeding 10, compared to 23/80 (28.7%) at 
baseline.  Among 34 participants with baseline CAC score of 0, 25 (73.5%) has a score of 0 at 
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follow up.  The remaining nine had a median CAC score of 19.6 and 6 of 9 had a follow-up CAC 
score > 10.  Plots of the baseline CAC (horizontal axis) and follow-up CAC scores (vertical axis) 
are shown (Figure 2,3,4).     
Progression of existing CAC (i.e. > 0) was defined as a 1.5 CAC increase.  Based on our 
definition, thirty-eight subjects (52.0%) were “progressors” and thirty-five were identified as 
“non-progressors”.  “Progressors” and “non-progressors” were similar with regard to serum 
lipids, exposure to HAART, family history, and use of lipid-lowering medications. (Table 14)    
Univariate analysis explored the relationship of a range of variables to CAC progression. 
(Table 15) Variables with a marginally significant relationship to progression (i.e., p<0.20) were 
considered in the multivariate model; these included baseline CAC, smoking, family history and 
aorta volume score.  Analysis using only progression as the outcome of interest, revealed an odds 
ratio (OR) for age of 1.06 per year (p=0.05), equivalent to an approximate doubling in 10 years 
(OR 1.98).  The OR for current smoking was 2.58 (p=0.08). (Table 15) Use of lipid-lowering 
medication was associated with lower odds of CAC score doubling, however was not significant.  
6.3.6 Discussion 
In this male population with well controlled HIV-infection, chronic use of HAART did not 
impact the progression of sub-clinical coronary atherosclerosis as measured by EBT.  In contrast, 
traditional atherosclerosis risk factors of smoking and advancing age, were borderline predictive 
of subclinical coronary atherosclerosis. The median duration of treatment with HAART in this 
population was in excess of 5 years (at baseline), longer than that of participants in the three 
previous studies utilizing EBCT in HIV-positive populations. (77-79)  Talwani and colleagues 
compared the CAC scores of HIV-infected men (n=60), aged 40 years and older (mean 47; range 
40-66 years) to age and race-matched male HIV-negative controls (n=180). (77) Subjects in 
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either arm had no history of treated hyperlipidemia or coronary artery disease; those in the HIV-
positive arm include both HAART-exposed (mean treatment duration 25.9 months) and 
HAART-naïve. CAC, defined as any score greater than 0 for 4 vessels, was detected in 33% of 
HIV-infected cases and 39% of controls (p=0.26). (77) Clinically significant CAC, as defined as 
a total score > 75th percentile, was documented in 18% of cases and 17% of controls, revealing 
no significant difference. (77)   No significant differences in either total or age-specific CAC 
scores were found between pairs of cases receiving protease inhibitors and their controls.   In 
both study arms, traditional coronary risk factors did predict the presence of CAC. (77)  
Conflicting results were reported by Robinson in a smaller study of CAC in treated HIV-infected 
patients. (78)   In this work, 22% of HIV-infected men (n=27, mean age 43.5. range; 30-60 
years) had CAC scores > 90th percentile compared to 7% of HIV-negative age-matched controls 
(n=81,  p = .034).(78) This study, however, was limited by lack of adjustment for traditional 
CAD factors. Among HIV-infected patients, smoking rates exceeded 81% compared to a 
smoking rate of 41.7% in the control group. (78) 
 In a study conducted among HIV-infected African-American men and women  (n=98), 
Lai and colleagues compared lipid profiles, red blood cell indices, C-reactive protein levels, and 
CAC in patients taking PI (n=55, mean age 39.3, +/- 4.5 years) and those who were not (n=43, 
mean age 37.8 +/- 5.1 years). (79)  The only statistically significant finding was a small 
difference in the proportion of total calcium volume scores > 5 among non –PI users compared to 
users of nelfinavir (p<0.05), ritonavir (p<0.05) or saquinavir (p<0.05). (79) No significant 
differences were found in the proportion of total calcium volume scores > 5 among non-PI users 
compared to users of indinavir, lopinavir or saquinavir/ritonavir combination. (79)    Our study is 
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the first to prospectively document CAC in men treated with highly active antiretroviral therapy 
for HIV-infection.  
Dyslipidemia at baseline was relatively common among our cohort 63/80 (78.8%), which 
would be expected in this population given the duration of HAART.  As concern about  
HAART-induced dyslipidemia on cardiac outcomes has increased, clinicians have been more 
aggressive to recommend lipid-lowering therapy. (4)  Our data reflect this trend, as 27.5% of our 
subjects were on lipid- lowering medications at baseline and half (42.5%) of these had a baseline 
CAC exceeding 10.  The true relationship, however, between dyslipidemia and CAC may be 
confounded by treatment with lipid lowering medications.  The duration of treatment with the 
lipid lowering medications was not quantified and may further impact these results.   
 CAC scores between 0 and 10 generally indicate minimal risk for future cardiac events 
(24) therefore, we chose CAC scores of zero, <10 and >10 as our study stratifications. The 
prevalence of clinically significant CAC scores (CAC >10) was only 23/80 (28.7%) and was 
associated with age and family history of cardiovascular disease in our univariate analysis.  The 
prevalence of clinically significant CAC scores in our study was similar that described by 
Talwani, et al, who documented “detectable” CAC (defined as CAC > 0) in 33% of HAART-
treated HIV-infected subjects (n=60).(21)  A notable difference, however was that the mean 
duration of HAART treatment  in the Talwani study was only 25.9 months, significantly less 
than the mean duration of 4.69 years at baseline of this study (median 5.01 years). (77)    
In our study, five individuals had CAC scores exceeding 100, a level that confers 
significantly increased cardiac risk (92).  Of these five, follow-up scores were available for four, 
and calcium volume scores ranged from 267-597.  These increases are consistent with reports of 
rapid atherosclerotic progression once sub-intimal inflammation and calcification begins.   
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The design of this study allowed for investigation of incidence of CAC over a period of 
2.7 years.  Fifty-two of the 57 participants with baseline CAC less than 10 had follow- up scans.  
Follow-up CAC scores exceeding 10 were found in 15 participants, yielding an incidence of 
clinically significant CAC of 28.8% over a 2.7 year period (Figure 1).  
Research regarding calcification of the thoracic or abdominal aorta has not been as 
extensive as the coronary arteries using EBCT, and generally focuses on subpopulations with 
existing cardiovascular risk factors, such as dyslipidemia (93) or cardiovascular disease 
equivalent such as diabetes mellitus. (94). The process of atherosclerosis occurring 
simultaneously in multiple vascular beds is common, and patients with coronary artery disease 
often have peripheral and cerebral vascular disease. (95,96)  In our study, the baseline abdominal 
aorta calcium score was at least marginally significant on a univariate scale (0.03 with rank-sum 
test and 0.10 with the logistic model), but was also correlated with the potentially significant 
predictors of age and baseline CAC, (with correlation coefficients of 0.45 and 0.66 respectively).  
It did not affect results of the presented multivariable models.  These findings are similar to a 
previous study by Post and colleagues, who documented a strong association between increasing 
age and thoracic aortic calcification among a cohort of 614 Amish subjects. (97) Our results do 
not support the finding of abdominal aorta calcification as an independent predictor of 
progression of coronary calcification, which may be attributable to our small sample size and/or 
the variance of the aorta calcium scores.     
   
This prospective study design allowed for identification and description of characteristics 
associated with CAC score progression. Progressors and non-progressors were similar in the 
majority of characteristics except smoking and age. HAART appeared to play no role in CAC 
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score progression, and in fact, the median duration of HAART treatment was longer among non-
progressors (5.15 years) than progressors (4.8 years).     
Duration of HAART was not associated with either prevalent or incident CAC.  This 
finding contradicts previous work by Robinson et al that found a modestly elevated level of CAC 
in HIV-infected patients treated with HAART, compared to HIV-uninfected controls. (78)  
Robinson’s study, however, did not control for smoking which varied significantly between the 
HIV-infected subjects (81.5%) and the controls (4.7%). (78). 
Our study is limited in three important ways. It excluded women. Despite the 
increasingly recognized relevance of gender-related differences in CAD risk factors and 
outcomes, our study could not address this. Additionally, our overall sample size was small, as 
only 73 subjects had both baseline and follow up data.  Larger prospective studies have now 
been initiated at all four MACS study sites. Finally, our study was limited by the relatively small 
numbers of participants with baseline CAC scores in excess of 100, as CAC progression is most 
clinically significant among those with higher baseline scores.  
Shortly after protease inhibitors therapy became available, accounts of myocardial 
infarctions surfaced among HAART-treated patients without traditional CAD risk factors. These 
accounts prompted suspicion of accelerated atherosclerosis and increased cardiovascular 
morbidity and mortality in individuals treated for HIV-infection. As methods to measure sub-
intimal calcium have become available and as such calcium accumulation has become correlated 
with the risk for future cardiac events, prospective studies have tried to evaluate the presence of 
CAC among those with HIV infection, with particular emphasis on those treated with HAART.  
Three such previously published cross-sectional studies of CAC scores in HIV-infected subjects 
have provided conflicting results. (77-79)  No prior studies, however, have published data 
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regarding the progression of CAC in HIV-infected subjects. Our data do not support indicate that 
chronic exposure to HAART promotes the development or progression of subclinical 
atherosclerosis.    Instead, our data indicate that the strongest risk factors for CAC score 
progression are increasing age and smoking, reinforcing the need stay vigilant in recommending 
and assisting with smoking cessation for all patients.  
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Table 12.  Baseline characteristics stratified by baseline CAC scores 
 
 Overall 
N=80 
CAC= 0 
N=38 
 
CAC < 10 
N=19 
CAC > 10 
N=23 
Age (years) 
Median 
[IQR] 
 
 
44.7 
[42.2, 49.8] 
 
43.8 
[41.8, 46.9] 
 
 
44.6 
[40.8, 47.5] 
 
49.8 
[44.5, 55.5] 
p=0.0016 
 
Duration of 
HAART (years) 
Median 
[IQR] 
 
 
 
5.01 
[3.95, 5.68] 
 
 
5.11 
[3.69, 5.62] 
 
 
 
 
4.44 
[3.78, 5.47] 
 
 
5.57 
[4.66, 5.75] 
p=0.2571 
CD4+ count 
(cells / mm3) 
Median 
[IQR] 
 
 
 
619 
[409, 885] 
 
 
618.5 
[385.2,883] 
 
 
535 
[403, 928] 
 
 
679 
[480, 957] 
p=0.7505 
 
HIV Viral load 
(cells / mm3) 
Median 
[IQR] 
 
 
 
50 
[50, 641] 
 
 
50 
[50, 50] 
 
 
50 
[50,50] 
 
 
 
50 
[50, 1400] 
p=0.9792 
 
Positive family 
history of CAD 
(%) 
 
29/79 
^^ 
36.7% 
 
11/38 
28.9 % 
 
4/18 
22.2% 
 
 
14/23 
60.8% 
p=0.01507 
 
Ever Smoked 
(versus Never) 
(%) 
 
 
37/80 
46.2 % 
 
15/38 
39.4 % 
 
8/19 
42.1 % 
 
14/23 
60.8 % 
p=0.2456 
 
Abdominal        
aorta calcium 
volume score 
Median 
[IQR] 
 
 
 
 
15 
[0.0, 156.5] 
 
 
 
2.41 
[0.0, 19] 
 
 
 
19 
[0.0, 85.5] 
 
 
 
191.0 
[31.86, 739] 
 
 
^^ Only 79 men could relate family history 
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Table 13. Baseline Lipid Testing and use of lipid lowering medication stratified by baseline 
CAC scores 
 
 Overall 
N=80 
CAC = 0 
N=38 
CAC <10 
N=19 
CAC >10 
N=23 
Total Cholesterol 
(mg/dL) 
Median 
[IQR] 
 
202.0 
[187.3, 239.3] 
 
 
204.0 
[179.8, 252.5] 
 
204.0 
[195,235.5] 
 
197 
[183.0, 223.0] 
p=0.4993 
 
HDL 
(mg/dL) 
Median 
[IQR] 
 
 
39.6 
[33.5, 45.6] 
 
40.4 
[33.8, 46.0] 
 
39.9 
[37.4, 49.3] 
 
38.9 
[32.0, 43.2] 
p=0.5947 
 
LDL 
(mg/dL) 
Median 
[IQR] 
 
 
114.5 
[96.8, 148.3] 
 
128.0 
[98.0, 167.0] 
 
 
 
114.5 
[107.0, 143.0] 
 
107.0 
[93.0, 137.0] 
p=0.2818 
Triglycerides 
(mg/dL) 
Median 
[IQR] 
 
202.0 
[118.0, 326.0] 
 
 
171.5 
[111.3, 266.5] 
 
240.5 
[172.0, 480.8] 
 
262.0 
[116.0, 394.5] 
p=0.2284 
 
N (%) taking 
lipid lowering 
medications 
22/80 
27.5% 
5/38 
13.1% 
7/19 
36.8% 
10/23 
43.4% 
p=0.0213 
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 Figure 2.  Plot of follow-up by baseline calcium levels – baseline levels < 10 
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 Figure 3. Plot of follow-up by baseline calcium levels – baseline levels ≥ 10 but < 100 
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 Figure 4. Plot of Follow-up by baseline calcium levels – baseline levels ≥ 100 
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Table 14. Characteristics of progressors and non-progressors 
 
 
Variable Progressors 
N=38 
Non-progressors 
N=35 
Age (years) 
Median 
[IQR] 
46.03 
[43.38, 52.34] 
44.06                  
[40.87, 48.36] 
p=0.04447 
Cholesterol (mg/dL) 
Median 
[IQR] 
 
 
197.5 
[188.0, 225.5] 
 
202.0 
[179.0, 241.0] 
p=0.7196 
HDL (mg/dL) 
Median 
[IQR] 
 
38.45 
[32.38, 45.08] 
 
42.10 
[37.50, 47.85] 
p=0.1182 
LDL (mg/dL) 
Median 
[IQR] 
 
 
113.0 
[96.0, 143.0] 
 
119.50 
[96.25, 149.80] 
p=0.6087 
Triglycerides (mg/dL) 
Median 
[IQR] 
 
 
222.5 
[118.8, 417.8] 
 
189.0 
[112.5, 280.0] 
p=0.4423 
Duration of HAART 
(years) 
Median 
[IQR] 
 
4.865 
[3.688, 5.678] 
 
5.150 
[4.105, 5.635] 
p=0.7114 
Baseline CAC score 
Median 
[IQR] 
 
9.4750 
[0.5475, 33.100] 
 
0.000 
[0.00, 0.725] 
p=0.00001132 
Current smokers 
N 
(%) 
 
 
21/38 
55.2 % 
 
 
11/35 
31.4 % 
p=0.07609 
Positive family history of CAD 
N 
(%) 
** unknown family history for 
one non-progressor 
 
17/38 
44.7 % 
 
10/34 ** 
28.5 % 
p = 0.2726 
Users of lipid-lowering 
medications 
N 
(%) 
 
11/38 
28.9 % 
 
9/35 
25.7 % 
p = 0.9627 
 
Abdominal aorta calcium 
volume score 
Median 
[IQR] 
 
 
39 
[3.66, 272.2] 
 
 
4.0 
[0.0, 58.5] 
p=0.031 
 
 82 
Table 15. Unadjusted logistic models for predicting a 1.5 fold increase in CAC scores 
 
 
Variable Unadjusted Odds 
Ratio 
P-
value 
Age 1.1065 0.0217 
Cholesterol 0.998 0.628 
HDL 0.985 0.428 
LDL 0.994 0.300 
Triglycerides 1.0009 0.375 
Duration on HAART 0.981 0.911 
Baseline Calcium Score 1.0558 0.0227 
Ever Smoking 2.7999 0.0397 
Family history of CVD 1.943 0.182 
Lipid lowering meds 1.1769 0.757 
Abdominal aorta score 1.0015 0.106 
 
Table 16.  Multivariable logistic model for predicting a 1.5-fold increase of CAC scores 
Variable Adjusted Odds Ratio P-value 
Age 1.068  (10 year OR 1.98) 0.053 
Smoking 2.568 0.089 
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7.0  FINAL SYNTHESIS AND CONCLUSIONS 
There is no dispute that highly active antiretroviral therapy (HAART) has dramatically 
decreased the rates of opportunistic infections, delayed the diagnosis of AIDS and improved life 
expectancy in those with HIV-infection. Initially, the immediate need to suppress the viral 
burden and improve immunologic status was paramount and considerations of the long-term 
consequences of these therapies were of minimal importance. However, with increasing follow-
up times, clinicians now know that these therapies are associated with substantial atherogenic 
lipid changes and it is possible that they will cause significant morbidity and mortality related to 
accelerated atherosclerosis. Clinicians have become vigilant in screening for, and treating 
induced metabolic toxicities even in the absence of physical changes as they are likely to precede 
the physical lipodystrophic findings. 
 
Treatment for HIV-infection is life-long. As such, the adverse effects of such therapy 
have become a growing public health concern. Although HIV–LS syndrome has just recently 
been acknowledged, it has already impacted trends in treatment, antiretroviral adherence and the 
physical appearance of those affected. Whereas AIDS wasting syndrome had some treatment 
options, (albeit not always successful) of high calorie diets, appetite stimulants, human growth 
hormone, enteral tube feedings, and total parenteral nutrition, HIV-LS has no recognized 
treatment.  Savvy clinicians know that substitution of stavudine or zidovudine with abacavir can 
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improve lipoatrophy; (98) other than that, patients are left only with strategies of concealment 
rather than treatment for HIV-LS. Within the MACS, we’ve heard several anecdotal accounts of 
the aesthetic and cosmetic effects of the body habitus changes.  Those most severely affected 
attempt to hide parts of their bodies because they fear recognition of  their HIV-infection by 
others.  Men have explained how they avoid wearing shorts in public and intentionally grow 
facial hair to minimize the appearance of their facial lipoatrophy.  Photographing the body 
habitus changes has validated self-reports of both the development of, and worsening of, the 
syndrome.  In the most extreme cases, patients have pursued surgical intervention for their HIV-
LS.  Unfortunately, such intervention is not curative and most often provides only temporary 
improvement.  One Pitt Men’s Study participant underwent liposuction of his growing 
dorsocervical fat pad, only to have the fat pad return several months later.  Over the past several 
years, Pitt Men’s Study participants with HIV-LS have graciously consented to photography 
knowing we were documenting the abnormal distribution of body fat as a consequence of 
treatment for HIV-infection. These photographs are now being used to improve the consistency 
and reliability of data collected MACS-wide.  Clinicians, researchers and patients are eager to 
document the long-term effects of some of the newer antiretroviral medications.  Hopefully, the 
negative effects on lipid profiles and related physical lipodystrophic changes will be fewer than 
with the earlier antiretroviral medications.   
HAART induced dyslipidemia has been well described and clinicians now monitor serum 
lipids and treat with lipid lowering medications as indicated.  Data from the MACS support this 
trend in treatment with a report of 34% of subjects prescribed lipid-lowering medications. (1) In 
our study utilizing EBCT, we documented dyslipidemia in 78% of subjects. Twelve subjects had 
serum triglycerides > 400 mg/dL, including three with levels in excess of 1,000mg/dL. 
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Pharmacologic treatment for hyperlipidemia was also common, with 22 participants treated at 
baseline.  Effective management of antiretroviral induced hyperlipidemia will continue to be a 
challenge as HIV-infected patients enjoy delayed progression to AIDS with longer life 
expectancy.  
Fasting hyperglycemia and insulin insensitivity are also important components of HIV-
LS, and their prevalence have been widely documented. (3,13,22,24,25) Although the processes 
of hyperglycemia and insulin resistance are separate from hyperlipidemia, they are synergistic 
with regard to the development and progression of atherosclerosis.  The extent to which 
atherogenesis is a complication of HIV-LS is still unknown. The current concern of accelerated 
atherosclerosis (and subsequent morbidities of cerebrovascular disease, coronary artery disease 
and peripheral vascular disease) is real. Among the general public, these vascular conditions 
generally commence at the same time, although the clinical manifestations may not appear 
simultaneously because of vessel size, development of collateral vessels and oxygen demands of 
the distal tissues.  How these vascular conditions progress in the presence of a chronic immune 
activation due to HIV-infections remains unknown.  The effect of HIV-infection and its 
treatment on cardiac risk is being explored in many studies.  These studies vary widely in their 
outcome of interest and include myocardial infarction, coronary calcification and/or angiography 
findings. Despite the differences in outcomes, traditional risk factors of family history and 
smoking are consistently found to affect cardiac risk.  Traditional advice to lower cardiac risk 
may not be feasible among those infected with HIV.  For example; a diet low in saturated fat 
may be recommended for “heart health” yet the HIV-infected patient may be struggling to 
maintain body weight. Or, peripheral neuropathy may limit opportunities for aerobic exercise. 
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My EBCT study endorsed two important concepts of atherosclerosis. First, is how the 
process of atherosclerosis occurs simultaneously in multiple vascular beds.  The subject with the 
highest abdominal aorta score at baseline (5612) was one of only five men who had a baseline 
CAC score > 100. Similarly, the subject with the highest baseline CAC score had a baseline aorta 
volume score of 1596. The other important concept illustrates that once the process of 
atherosclerosis begins, it continues to progress.  The patient with greatest CAC score at baseline 
(297) also had the greatest score at follow-up (598).  Both of these scores suggest likelihood of a 
future cardiac event.    
The findings in my study utilizing EBCT are similar to findings found MACS-wide.  
Specifically, Kingsley and colleagues did not find that chronic use of HAART (>8 years) was 
associated with an increased prevalence of CAC>10 Agatston units. (99) Rather, this study found 
traditional cardiovascular risk factors of increasing age and smoking as contributors to the 
development of subclinical atherosclerosis. Kingsley’s study had a larger cohort and was also 
able to identify increased LDL, hypertension and decreased HDL as predictors of risk. (99) 
Findings in our EBCT study, and the MACS study,  are similar to results documented by 
Depairon who used ultrasound detected thickening of peripheral arteries as a surrogate for 
coronary artery disease.(100) In that study, a multivariate logistic regression analysis revealed 
age and cigarette smoking as significant risk factors and not exposure to protease inhibitors. 
(100)  Some of the largest prospective studies in the world have documented increased risk for 
myocardial infarction.  The MACS is now investigating additional measures of atherosclerosis.  
They are prospectively measuring the intima-media thickness of the carotid arteries and 
repeating EBCT imaging for the coronary vasculature. The three-year follow-up for that study 
will be completed in September 2008.     
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Early studies showed associations between exposure to protease inhibitors and 
myocardial infarctions. (10,31) One of the most recent studies evaluated cardiovascular risk 
among patients with HIV-infection and documented a relative risk (RR) of 1.75 (95% confidence 
interval 1.51-2.02; p<0.0001) of acute myocardial infarction after adjusting for age, gender, race, 
hypertension, diabetes mellitus and dyslipidemia.  (101) The RR was even higher for women in 
the gender-stratified analysis (RR 2.98 confidence interval 2.33-3.75 p<0.0001). It is not known 
why hard outcomes continue to be so strongly associated with exposure to antiretroviral 
medications, while subclinical atherosclerosis is not.  Perhaps the incubation time has not been 
long enough or maybe the myocardial infarctions related to HAART are the result of sudden 
complete arterial occlusion that is not preceded by sub-intimal calcification. This speculation 
warrants further investigation.  
Historically, HIV related morbidity and mortality was from opportunistic infections and 
malignancies.  It is reasonable to assume that HIV/AIDS will present ongoing challenges of viral 
resistance and new challenges long-term complications of antiretroviral therapy.  In this work, 
we have addressed our specific aims and raised several new questions. Questions such as: are 
sub-intimal changes simultaneously occurring in other vascular beds, such as the peripheral 
vascular system or cerebrovascular system? How will peripheral and visceral adipocytes respond 
to 30 years + exposure to HAART? How will insulin sensitive tissues respond to 30 years + 
exposure to HAART? Does HIV-LS phenotype III occur as natural progression of 
lipohypertrophy? And finally, how many other phenotypes of HIV-LS exist? 
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Introduction
HIV-associated lipodystrophy syndrome (HIV-LS) was 
first described in 1998 and involves a constellation of 
findings including hyperglycemia, insulin resistance, 
hyperlipidemia and body habitus changes.    
Unfortunately, no strict diagnostic criteria have 
been established, leaving documentation of the 
syndrome to the somewhat subjective patient self-
report and/or clinician report. 
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HIV-Lipodystrophy Syndrome
Whereas AIDS wasting syndrome has 
been associated with 
immunosuppression and high viral 
burden, HIV-LS has been documented 
with immunocompetence and 
suppressed viral concentration.   
 
Defining HIV-LS
HIV-LS consists of both lipoatrophy and 
lipohypertrophy.  
Lipoatrophy involves the face (temporal 
area and cheeks) and extremities 
while the lipohypertrophy involves the 
breasts, dorsocervical fat pad and 
visceral fat of the abdomen. 
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Defining HIV-LS
Clinicians within the MACS evaluate each subject during 
every clinic visit for the presence and severity of HIV-LS via self-
report and physical examination.  
The severity of HIV-LS has been quantified by a scale using 
mild/moderate and severe descriptors for each of the 
affected body areas. 
Mild is documented for changes that are evident to clinician with 
close inspection; moderate is used for changes that are 
evident to clinician without specifically looking for them; and 
severe reflects changes that are evident to a non-medical 
person by casual observation.
 
Defining HIV-LS
HIV-LS has been described within the 
MACS via three phenotypes.  
Phenotype I involves lipoatrophy only, 
whereas Phenotype II involves mixed 
findings of peripheral fat loss and 
visceral fat accumulation.   Recently, 
Phenotype III has been proposed 
which involves supra-diaphramatic
accumulation of adipose tissue which 
extends laterally from the breasts.   
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HIV-LS
Using prospectively collected data, HIV-LS 
cases have been deemed as “stable”
referring to individuals who are consistently 
observed with the same phenotype, 
“developmental” referring to individuals 
initially unaffected (or mildly affected) and 
on subsequent examination are found to be 
developing lipodystrophic changes, or 
“transitional” referring to progression from 
one phenotype to another. 
 
HIV-LS
The quantification of lipodystrophic changes among MACS 
participants have been used in conjunction with standardized 
anthropometric measurements (NHANES III: including height, 
weight, arm, thigh, waist and hip circumferences) and 
laboratory testing for metabolic abnormalities (lipid profiles, 
glucose, insulin and glycosolated hemoglobin).
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Defining HIV-LS
Body habitus changes can be difficult to appreciate due to the natural 
variation of body shape, contour and size.  As such, the appearance 
of some individuals in the general population may initially be 
perceived as “mild lipodystrophy” as a consequence of weight gain  
or aging.
However, with close inspection and careful consideration, experienced 
clinicians are able to detect true lipodystrophic changes even when 
they are subtle. 
 
Purpose
The purpose of this manual is to 
provide examples of mild, moderate 
and severe lipodystrophic findings in 
order to establish consistency of 
assessment of HIV-LS among all four of 
the MACS sites.  
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Performing the HIV-LS 
Assessment
 
General Instructions
In order to collect the most reliable data, assessment for HIV-LS 
should be performed on every MACS participant regardless of HIV 
serostatus.  
The assessment should begin with the self-report questionnaire.  Subjects 
are initially asked if they have noticed any change in the amount or 
distribution in body fat in the last 6 months or since their last MACS 
visit.  If a change has been noticed, subjects are asked about 
specific body areas affected by lipodystrophy, and current severity 
of fat loss / gain in those areas.  
Note that subjects are to describe the current severity of each area (as 
mild, moderate or severe) and not the degree of change since last 
visit.  
Subjects are also asked about behaviors that may influence their body 
fat such as recent changes in dietary or exercise habits, use of
growth hormones or steroids, change in HIV-treatment medications, 
or cosmetic surgery. 
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Inspection
Inspection must be completed with the 
body area fully exposed.  The subject should 
be instructed to relax, and to avoid 
adapting or changing their posture or 
physique.  
Inspection of the breasts, abdomen and 
buttocks should be done at eye-level.  
Inspection of the abdomen for the presence 
of visceral fat can be facilitated by also 
having the individual supine while inspecting 
for “bulging” of the flanks. 
 
Facial Lipoatrophy
Lipoatrophy of the face is evident in 
the temporal areas and nasolabial
folds.  The sunken appearance of the 
face can be appreciated in the frontal 
and side-views. 
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Mild Facial Lipoatrophy
• Note the 
pronounced 
nasolabial folds.
 
Moderate Facial Lipoatrophy
• As lipoatrophy of 
the face progresses, 
the prominence of 
the nasolabial folds 
fades and 
hollowing of the 
cheeks occurs just 
below and anterior 
to the zygomatic
arch.
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Severe Facial Lipoatrophy
• Severe facial 
lipoatrophy will be 
evident with both 
hollowing of the 
cheeks and a 
depression of the 
temporal region.  
 
Lipoatrophy of Extremities
• Lipoatrophy of the 
extremities 
becomes evident 
with:
– venous prominence
– obvious bony 
landmarks and 
– increased muscle 
definition without an 
increase in muscle 
bulk.
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Mild Lipoatrophy of Extremities
• The venous 
prominence in this 
photograph 
suggests mild 
lipoatrophy of the 
extremities.
 
Moderate Lipoatrophy of the 
Extremities
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Severe Lipoatrophy of the 
Extremities
 
Severe lipoatrophy of the upper 
extremity
• This photograph 
clearly shows the 
loss of 
subcutaneous fat of 
the shoulder and 
arm.  
• Facial atrophy is 
also evident in this 
participant.
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Severe Lipoatrophy of Upper 
and Lower Extremities
• Fat loss of the extremities 
involves simultaneous loss of 
the arms and legs. 
• This photograph clearly 
documents the severe 
lipoatrophy of the face, 
upper and lower extremities.  
 
Deep Depression of the Medial  
Thigh
• Subcutaneous fat 
normally accumulates 
at the medial thigh.  As 
lipoatrophy of the 
lower extremity 
progresses, a deep 
depression develops 
medial to the vastus
medialis and adductor 
magnus as shown here.
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Severe Lipoatrophy of the Legs
• Venous prominence 
is a characteristic 
finding in 
subcutaneous fat 
loss of the 
extremities as 
experienced by this 
subject.  
 
Lipoatrophy of the Extremities
• Eventually, loss of all 
perigenicular fat 
becomes obvious, 
and the lower 
extremities look too 
thin to support the 
weight of the body 
as shown here.
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Lipoatrophy of the Buttocks
Loss of fat in the gluteal region is 
common, and is seen with 
simultaneous loss of fat of the 
extremities.
With severe loss of the buttocks, striations 
of the gluteus maximus may become 
obvious.
 
Moderate Lipoatrophy of the 
Buttocks
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Severe Lipoatrophy of the 
Buttocks
• Upon inspection from 
the side view, the loss 
of fat in the gluteal
region is particularly 
evident.  In this 
photograph, severe 
visceral fat 
accumulation can also 
be appreciated which 
is characteristic of 
phenotype II of HIV-LS.  
 
Mild Hypertrophy of the Breasts
• Although more 
common among 
women with HIV-LS, 
breast enlargement 
has  been 
documented in men. 
• Hypertrophy of the 
breasts can be 
appreciated in the side 
and frontal views.   
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Mild Hypertrophy of the Breasts
** Both images are from the same study participant.
 
Moderate Lipohypertrophy of 
the Breasts
** Both images are of the same study participant
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Moderate Lipohypertrophy of 
the Breasts
 
Severe Lipodhypertrophy of the 
Breasts
• As the breasts 
increase in size, the 
nipples become 
laterally displaced 
as evident here.
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Severe Lipohypertrophy of the 
Breasts
 
Severe Lipohypertrophy of the 
Breasts
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Visceral Fat Accumulation
Visceral fat accumulation causes 
abdominal distention.  Most often, the 
overlying skin of the abdomen is tight, 
which is in contrast to accumulation of 
subcutaneous fat which causes the 
skin to become loose and sagging.  
Visceral fat accumulation can be 
confused with ascites and is similar in 
appearance to a gravid abdomen.    
 
Visceral Fat Accumulation
• As visceral fat 
accumulates, the 
oblique and rectus
abdominus muscles are 
defined, as if being 
pushed forward by the 
underlying viscera and 
fat.  This is in contrast to 
accumulation of 
subcutaneous fat 
during which the 
definition of the 
oblique and rectus
abdominus muscles is 
lost. 
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Mild Visceral Fat Accumulation
 
Moderate Visceral Fat 
Accumulation
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Severe Visceral Fat 
Accumulation
**  Both images are from the same study participant
 
Severe Visceral Fat 
Accumulation
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Mild Dorsocervical Fat Pad
 
Severe Dorsocervical Fat Pad
• This photograph 
illustrates a typical 
presentation of 
phenotype II.  Note 
the lipoatrophy of 
the face with 
simultaneous fat 
accumulation of 
the abdomen and 
dorsocervical fat 
pad.
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Body Habitus Changes 
Clinicians within the MACS evaluate each subject during 
every clinic visit for the presence and severity of body habitus
changes via self-report and physical examination.  
The severity of the changes has been quantified by a scale using
mild/moderate and severe descriptors for each of the 
affected body areas. 
Mild is documented for changes that are evident to clinician with 
close inspection; moderate is used for changes that are 
evident to clinician without specifically looking for them; and 
severe reflects changes that are evident to a non-medical 
person by casual observation.
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Purpose
The purpose of this manual is to 
provide examples of mild, moderate 
and severe findings in order to 
establish consistency of assessment 
among all four of the MACS sites.  
 
Mild Facial Lipoatrophy
• Note the 
pronounced 
nasolabial folds.
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Moderate Facial Lipoatrophy
• As lipoatrophy of 
the face progresses, 
the prominence of 
the nasolabial folds 
fades and 
hollowing of the 
cheeks occurs just 
below and anterior 
to the zygomatic
arch.
 
Severe Facial Lipoatrophy
• Severe facial 
lipoatrophy will be 
evident with both 
hollowing of the 
cheeks and a 
depression of the 
temporal region.  
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Mild Lipoatrophy of Extremities
• The venous 
prominence in this 
photograph 
suggests mild 
lipoatrophy of the 
extremities.
 
Moderate Lipoatrophy of 
Extremities
• Lipoatrophy of the 
extremities 
becomes evident 
with:
– venous prominence
– obvious bony 
landmarks and 
– increased muscle 
definition without an 
increase in muscle 
bulk.
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Severe lipoatrophy of the upper 
extremity
• This photograph 
clearly shows the 
loss of 
subcutaneous fat of 
the shoulder and 
arm.  
• Facial atrophy is 
also evident in this 
participant.
 
Severe lipoatrophy of the lower 
extremity
• Subcutaneous fat 
normally accumulates 
at the medial thigh.  As 
lipoatrophy of the 
lower extremity 
progresses, a deep 
depression develops 
medial to the vastus
medialis and adductor 
magnus as shown here.
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Mild Hypertrophy of the Breasts
 
Moderate Lipohypertrophy of 
the Breasts
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Severe Lipohypertrophy of the 
Breasts
• With severe 
lipohypertrophy of 
the breasts, the 
nipples become 
laterally displaced 
as shown in this 
participant. 
 
Mild Dorsocervical Fat Pad
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Moderate Dorsocervical Fat Pad
 
Severe Dorsocervical Fat Pad
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